US3536809A - Medication method - Google Patents

Medication method Download PDF

Info

Publication number
US3536809A
US3536809A US3536809DA US3536809A US 3536809 A US3536809 A US 3536809A US 3536809D A US3536809D A US 3536809DA US 3536809 A US3536809 A US 3536809A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
buccal
medicament
strip
progesterone
estrone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Norman Applezweig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0092Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine for holding medicines in, or fixing medicines on, a tooth, e.g. holder containing medicines fixed on a tooth

Description

United States Patent 3,536,809 MEDICATION METHOD Norman Applezweig, New York, N.Y., assignor to Alza Corporation, Palo Alto, Calif., a corporation of California No Drawing. Continuation-impart of application Ser. No. 492,301, Oct. 1, 1965. This application Feb. 17, 1969, Ser. No. 799,910

Int. Cl. A61j 7/00; A61k 9/00, 17/00 US. Cl. 42428 4 Claims ABSTRACT OF THE DISCLOSURE A method of administering medication employs a strip covering the medicament which is inserted between the gum and cheek so that absorption of the medicament at a predetermined interval through the buccal mucosa into the bloodstream may take effect, after which the strip is removed and discarded.

The present invention relates generally to improvements in the administration of medicaments and it relates more particularly to an improved method for introducing a medicament into the blood stream. This application is a continuation in part of application Ser. No. 492,301, filed Oct. 1, 1965 now abandoned.

The conventional methods of introducing a medicament into the blood stream are by direct injection and by oral administration, in the latter case the medicament being absorbed through tre membrane which lines the passage of the medicament. Many medicaments are completely ineffective or of radically reduced efficacy when orally administered since they either are not absorbed or are adversely affected before entering the blood stream and thus do not possess the desired activity. On the other hand, the direct injection of the medicament into the blood stream, while assuring no modification of the medicament in administration, is a diflicult, inconvenient and highly uncomfortable procedure and requires a high degree of skill.

Sublingual tablets and any other form of sublingual administration are subject to the limitations that there are smaller surfaces for the transmission through the mucosal membrane, that in the case of sublingual location a substance there placed causes salivation, and by reason of the additional fluid and the position in the mouth is likely to lead to swallowing of at least a portion of the medicament. Buecal tablets are known also but there are important drawbacks accompanying their use and they have enjoyed little success. In some instances larger dosages are required to be inserted in the buccal tablet than are needed in the case of the buccal strip of the present invention. In addition they usually take a great deal of time to deliver the medicament to the buccal surface. The buccal tablet also causes pressure between the lip and the gum, which may be uncomfortable and painful. This pressure also may cause the tablet to disintegrate and thus more of the contents arelikely to be swallowed.

It is therefore a principal object of the present invention to provide an improved method for the introduction of medication into the blood stream.

A further object of the present invention is to provide an improved method for the administration of hormones.

The above and other objects of the present invention will become apparent from a reading of the following description in which examples are given merely by way of illustration and are not intended to limit the scope of the invention.

It has been found that certain medicaments when slowly released to the oral mucosa and particularly to the buccal membrane are absorbed thereby and efficiently enter the blood stream and unexpectedly effect a highly superior therapy or activity. Thus, in a sense of the present invention contemplates the employment of a medication form for introducing a pharmaceutically active material into the blood stream for a predetermined period comprising a film or strip carrying a pharrnaceutically active material releasable therefrom in an aqueous medium for absorption through the oral mucosa buccal tissue. In another sense the present invention involves the method of introducing a medicament into the blood stream comprising positioning a fibrous absorbent strip carrying a medicament releasable therefrom in overlying contact with the oral mucosa buccal tissue.

While the present method is employed to great advantage in the administration of hormones, for example, progesterone, estrone, testosterone, cortisol, desoxycorticosterone, it may be employed to advantage with other medicaments, for example, protelytic enzymes such as trypsin, chymotrypsin, strepeokinase, streptodornase, appetite depressants, antispasmodics and sedatives, where rapid entrance to the blood stream is highly desirable.

The base of the subject medication form or buccal strip is advantageously an absorbent web such as a strip of woven or non-woven fabric, filter paper or cotton gauze, and is of a dimension which may be comfortably retained between the gum and cheek of the subject and can support in a releasable form a sufficient dosage of the medicament to be administered. The buccal strip may be advantageously between one and ten centimeters long, for example five centimeters, and between one-half and three centimeters wide, for example, one centimeter.

The medicament may be carried by the buccal strip in its pure state or it may be admixed with suitable carriers which facilitate the support of the medicament by the buccal strip and its suitable release to the buccal face. Examples of such carriers are Carbowax, polyvinylpyrrolidone, carboxymethyl cellulose, xgurn arabic and other water soluble or dispersible thickening agents and adhesives.

As an example of a medication form, its preparation and use in accordance with the present invention, a piece of Pellon 2100 (100% Polyamide fiber) fabric was immersed in a 20% dispersion of progesterone in a molten mixture of 15% Carbowax 400 and Carbowax 4000 to fully impregnate the fabric. The impregnated fabric was then allowed to cool. The progresterone carrying fabric is cut into one by two centimeter strips, each strip containing about 26 milligrams of progesterone.

In the administration of the progesterone in accordance with the present invention the subject merely places and retains the progesterone carrying buccal strip described above between the confronting faces of the gum and the cheek and in contact with the buccal membrane. The buccal strip releases the progesterone which directly enters the blood stream through the buccal membrane. The rate of release of the progesterone averaged about 2 mgm. minute and the buccal strip was substantially depleted of medicament in approximately 15 minutes. At the end of such period the strip is removed and discarded.

Subjectswho were administered progesterone in dosages of 26 mg. at intervals of 24 hours for five days by the use of the buccal strip medication form in the manner set forth above had withdrawal bleeding two to five days following cessation of medication.

These were patients who suffered from a variety of menstrual difiiculties and were not capable of spontaneous menstruation. Menstruation could be induced in such patients by intramuscular injection of mg. of progesterone. Following intramuscular progesterone, withdrawal bleeding could be demonstrated after four to five days.

Repeated use of buccal progesterone at intervals of one month, and even at shorter intervals, consistently induced withdrawal bleeding.

In contrast, subjects administered progesterone orally in the same dosages and at the same intervals as above failed to show any withdrawal bleeding. The literature reports that, on occasion, withdrawal bleeding has been induced in patients following oral administration of dosages of 500 mg. to 1500 mg. of progesterone. Such an effect cannot be obtained consistently however.

In another series of trials, buccal strips of size A" to 1" containing 2 mg. of estrone per strip were administered to patients, one strip per day for 15 days. It was found that approximately 95% of the estrone was removed from the buccal strip in approximately 15 minutes,

so that the rate of release of the estrone averaged about .133 mg. per minute. These patients were all either prepuberal or postmenopausal. In each case vaginal cystology showed castrate cells. After as little as four days, the vaginal cells showed 2 to 3+ estrogen effect, and after eleven days, a full 4+ estrogen effect. If estrone were administered orally to such patients, a dose of at least two to three times this amount would be required. In fact, estrone is almost never administered orally because of its comparative lack of efiectiveness by this route. Instead, orally active estrogen compounds such as ethinylestradiol, diethylstilbestrol or conjugated estrogens from pregnant mares urine are used for oral administration. Estrone can produce typical estrogenic vaginal cornification if administered intramuscularly in dosages of one milligram daily for five days. However, continued intramuscular administration must be avoided since this is painful and may cause tissue damage and narcosis.

A preferred estrone buccal strip was prepared by impregnating filter paper with an alcoholic solution of estrone. The final concentration of estrone in the dried strip was determined by weight after evaporation of the alcohol to be 2 mg. per square cm. The solution that was used contained 1 gm. dissolved in 250 ml. of 96% alcohol. When strips are made up which are 1 cm. in width they may be cut appropriately to fix the dosage level in each strip.

The progesterone unit dosage administered in the present manner is advantageously between and 50 milligrams and is administered at intervals between 12 and 72 hours. While the unit administration dosage of a hormone in the present form may be between 0.1 and 100 milligrams, the unit administration dosages of the hormones other than progesterone and their respective interval be- It was found that the buccal strips containing estrone, cortisol, testosterone and desoxycorticosterone were depleted of medicament when in contact with the buccal mucosa to the extent of 95 in about 15 minutes.

The preparation of the present medication forms employing therapeutic agents other than progesterone may be produced in the above manner, the medicament being applied either from a solution or dispersion thereof in water or an organic solvent which is compatible with the medicament or may be carried in any suitable water dispersible or soluble vehicle. The solvent or water is removed in any well known manner which will not adversely affect the medicament such as by freeze drying, or the like.

The particular medicament and the vehicles employed in connection with it generally determine the release of the medicament and therefore the time of its passage across the buccal mucosa. Generally speaking, it is not wise to provide for too quick a release time. It has been found that a range of release time of from 5 to 20 minutes is optimal. In each case the method of administration employed includes the step for discarding the same after substantial depletion of the medicament therefrom.

While there has been described a preferred embodiment of the present invention, it is apparent that numerous alterations, omissions and additions may be made without departing from the spirit thereof.

What is claimed is:

1. The method of securing the systemic effect of a medicament comprising positioning between the confronting faces of the gum and cheek and in contact with the buccal membrane a flexible absorbent removable and discardable non-ingested fabric, gauze or paper strip, of a dimension which may be comfortably retained between the gum and the cheek and can support in a releasable form from all surfaces to the buccal face a suflicient systemic dosage of the medicament to be administered, impregnated with a medicament releaseable therefrom, admixed in a suitable water-soluble or dispersible impregnant carrier adapted to obtain a predetermined average rate of direct release from the buccal strip through the buccal membrane directly into the blood stream of a preselected species of medicament and to obtain an approximate predetermined time period in which the buccal strip is substantially depleted of said medicament, in overlying contact with the oral mucosa from opposite faces of said strip, then removing and discarding the buccal strip after a predetermined approximate time period for substantial depletion of the preselected species of medicament.

2. The method of claim 1 in which the medicament is a hormone.

3. The method of claim 1 in which the medicament is a hormone selected from the group consisting of progesterone, estrone, testosterone, cortisol and desoxycorticosterone.

4. The method of claim 2 in which the strip contains from 0.1 mg. to mg. of said hormone.

References Cited UNITED STATES PATENTS 3,339,546 9/ 1967 Chen 424-28 XR 3,429,308 2/1969 Russell 1281 SHEP K. ROSE, Primary Examiner US. Cl. X.R.

US3536809A 1969-02-17 1969-02-17 Medication method Expired - Lifetime US3536809A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US79991069 true 1969-02-17 1969-02-17

Publications (1)

Publication Number Publication Date
US3536809A true US3536809A (en) 1970-10-27

Family

ID=25177075

Family Applications (1)

Application Number Title Priority Date Filing Date
US3536809A Expired - Lifetime US3536809A (en) 1969-02-17 1969-02-17 Medication method

Country Status (1)

Country Link
US (1) US3536809A (en)

Cited By (773)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US4292299A (en) * 1978-11-06 1981-09-29 Teijin Limited Slow-releasing medical preparation to be administered by adhering to a wet mucous surface
DE3237945A1 (en) * 1981-10-20 1983-05-05 Sandoz Ag Pharmaceutical compositions with sustained release
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
EP0206741A2 (en) 1985-06-18 1986-12-30 Merck Frosst Canada Inc. Leukotriene antagonists
US4667032A (en) * 1983-01-21 1987-05-19 Merck Frosst Canada, Inc. Phenothiazone derivatives and analogs
EP0239306A2 (en) 1986-03-27 1987-09-30 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4859667A (en) * 1983-01-21 1989-08-22 Merck Frosst Canada, Inc. Pharmaceutical compositions of phenothiazone derivatives and analogs
US4889720A (en) * 1986-09-01 1989-12-26 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form for use with tissues of the oral cavity
US4892736A (en) * 1983-10-07 1990-01-09 The Forsyth Dental Infirmary For Children Intra-pocket drug delivery devices for treatment of periodontal diseases
US4969871A (en) * 1989-02-15 1990-11-13 Alza Corporation Intravenous system for delivering a beneficial agent
US4985016A (en) * 1989-02-15 1991-01-15 Alza Corporation Intravenous system for delivering a beneficial agent
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
US5019382A (en) * 1986-11-06 1991-05-28 The Texas A&M University System Treatment of immuno-resistant disease with low-dose interferon
US5045059A (en) * 1989-02-15 1991-09-03 Alza Corporation Intravenous system for delivering a beneficial agent
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5173302A (en) * 1990-09-28 1992-12-22 Medtronic, Inc. Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs
US5250028A (en) * 1989-02-15 1993-10-05 Alza Corporation Intravenous system for delivering a beneficial agent using permeability enhancers
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5648396A (en) * 1991-02-04 1997-07-15 Sepracor Inc. Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
US5830456A (en) * 1986-11-06 1998-11-03 The Texas A&M University System Treatment of viral disease with oral interferon-α
US5910304A (en) * 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US5962464A (en) * 1997-02-11 1999-10-05 Sepracor Inc. Methods and compositions for treating allergic asthma using descarboethoxyloratadine
US6048879A (en) * 1998-06-15 2000-04-11 Sepracor Inc. Methods for treating apnea, apnea disorders, bulimia, and other disorders using optically pure (+) norcisapride
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6110973A (en) * 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
US6197788B1 (en) 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6410052B1 (en) 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
US20020090394A1 (en) * 1995-07-20 2002-07-11 Smithkline Beecham Plc Paroxetine controlled release compositions
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
US6432446B2 (en) 2000-02-03 2002-08-13 Bridge Pharma, Inc. Non-arrhythmogenic metabolite of oxybutynin
US6458374B1 (en) 1998-01-29 2002-10-01 Sepracor, Inc. Methods and compositions for treating chronic disorders using optically pure (+)-bupropion
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US20030032643A1 (en) * 1998-01-22 2003-02-13 Ascher John A. Pharmaceutically active morpholinol
US20030045726A1 (en) * 1996-08-12 2003-03-06 Muller George W. Novel immunotherapeutic agents
WO2003022259A1 (en) 2001-09-13 2003-03-20 Sepracor Inc. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
US20030064988A1 (en) * 1998-01-21 2003-04-03 Morgan Phillip Frederick Pharmaceutically active morpholinol
US6548518B2 (en) 1999-03-02 2003-04-15 Sepracor, Inc. Methods of treating gastro-esophogeal reflux disease using (-) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6548082B1 (en) 1999-03-01 2003-04-15 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6559165B1 (en) 1998-06-15 2003-05-06 Sepracor, Inc. Methods for treating bulimia using optically pure (−) norcisapride
US20030096812A1 (en) * 2001-04-25 2003-05-22 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-Quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US20030096019A1 (en) * 2001-07-02 2003-05-22 Currie Mark G. Methods of using norfluoxetine
US20030107149A1 (en) * 2001-10-12 2003-06-12 International Fluidics. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20030119168A1 (en) * 2000-02-03 2003-06-26 Corvas International, Inc. Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20030162816A1 (en) * 1999-09-17 2003-08-28 Gatlin Marjorie Regan Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US20030167524A1 (en) * 2000-12-19 2003-09-04 Rooijen Gijs Van Methods for the production of multimeric protein complexes, and related compositions
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
US6664397B1 (en) 1997-03-07 2003-12-16 Vernalis Research Limited Use of (+)mefloquine for the treatment of malaria
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
WO2004009558A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
US20040019211A1 (en) * 2002-05-31 2004-01-29 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US20040024031A1 (en) * 2002-05-03 2004-02-05 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US6709676B2 (en) 1999-12-20 2004-03-23 Schering Corporation Extended release oral dosage composition
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US20040147558A1 (en) * 2000-11-30 2004-07-29 Anthony Treston Synthesis of 3-amino-thalidomide and its enantiomers
US20040167199A1 (en) * 2002-11-18 2004-08-26 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20040180857A1 (en) * 1998-08-24 2004-09-16 Senanayake Chrisantha Hugh Methods of treating or preventing pain using sibutramine metabolites
WO2004078161A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20040186111A1 (en) * 2002-12-24 2004-09-23 Qun Sun Therapeutic agents useful for treating pain
WO2004081001A1 (en) 2003-02-13 2004-09-23 Banyu Pharmaceutical Co., Ltd. Novel 2-pyridinecarboxamide derivatives
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
US20040220144A1 (en) * 2002-10-15 2004-11-04 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US6825205B2 (en) 2002-09-25 2004-11-30 Euro-Celtique S.A. N-substituted hydromorphones and the use thereof
US20040248987A1 (en) * 2003-05-23 2004-12-09 Aberg A.K. Gunnar Smooth muscle spasmolytic agents
US20040247696A1 (en) * 2001-07-05 2004-12-09 Antelman Marvin S. Methods of using electron active compounds for managing conditions afflicting mammals
US20040260076A1 (en) * 2002-10-11 2004-12-23 Castillo Gerardo M. Isolation, purification and synthesis of procyanidin B2 and uses thereof
US20040258896A1 (en) * 2001-10-12 2004-12-23 Monosolrx Llc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20040268425A1 (en) * 2003-03-05 2004-12-30 Deliatroph Pharmaceuticals, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050008581A1 (en) * 2003-06-06 2005-01-13 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20050009782A1 (en) * 2003-07-09 2005-01-13 Comper Wayne D. Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
US20050014829A1 (en) * 2003-05-23 2005-01-20 Julius Remenar Sertraline compositions
US20050020692A1 (en) * 2003-07-24 2005-01-27 Ciofalo Vincent B. Treatment of heaves
WO2005009539A2 (en) 2003-07-23 2005-02-03 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6858589B2 (en) 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
US20050054666A1 (en) * 2003-09-04 2005-03-10 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
US20050065164A1 (en) * 2001-04-25 2005-03-24 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US20050070551A1 (en) * 2002-02-15 2005-03-31 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20050090516A1 (en) * 1994-12-30 2005-04-28 Muller George W. Novel substituted imides
US20050106248A1 (en) * 2003-11-17 2005-05-19 Manesh Dixit Extended release venlafaxine formulation
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
WO2005066126A1 (en) 2003-12-23 2005-07-21 Eli Lilly And Company Cb1 modulator compounds
US20050176757A1 (en) * 2004-01-07 2005-08-11 Aryx Therapeutics Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20050197392A1 (en) * 1999-04-06 2005-09-08 Sepracor Inc. O-desmethylvenlafaxine and methods of preparing and using the same
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20050203125A1 (en) * 2002-07-17 2005-09-15 Gerald Yakatan Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20050209295A1 (en) * 2004-03-16 2005-09-22 Kohn Leonard D Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
WO2005089767A1 (en) 2004-03-12 2005-09-29 Barton Aron Kamen Use of aminopterin for treating cancer and inflammatory disorders
US20050215617A1 (en) * 1999-09-03 2005-09-29 Apbi Holdings, Llc Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
US6951873B1 (en) 1999-04-27 2005-10-04 Pfizer Inc. Methods for treating age-related behavioral disorders in companion animals
US20050227971A1 (en) * 2004-04-08 2005-10-13 Wyeth Thioamide derivatives as progesterone receptor modulators
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US20050234084A1 (en) * 2002-05-31 2005-10-20 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
US20050234017A1 (en) * 2002-05-17 2005-10-20 Sol Barer Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
US20050239867A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
US20050260186A1 (en) * 2003-03-05 2005-11-24 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US6979463B2 (en) 1999-12-20 2005-12-27 Schering Corporation Stable extended release oral dosage composition
US20060003001A1 (en) * 2004-02-11 2006-01-05 John Devane Chronotherapeutic compositions and methods of their use
US20060004037A1 (en) * 2004-03-25 2006-01-05 Transform Pharmaceuticals, Inc. Novel tricyclic compounds and related methods of treatment
US20060014809A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
US20060030594A1 (en) * 2002-05-17 2006-02-09 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20060034815A1 (en) * 2004-08-06 2006-02-16 Hector Guzman Novel statin pharmaceutical compositions and related methods of treatment
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US20060052438A1 (en) * 2004-04-30 2006-03-09 Chi-Tang Ho Bioactive compounds and methods of uses thereof
US20060058365A1 (en) * 2004-08-06 2006-03-16 Kohn Leonard D Compositions and methods for treatment of colitis
WO2006049304A1 (en) 2004-11-02 2006-05-11 Banyu Pharmaceutical Co., Ltd Aryloxy-substituted benzimidazole derivatives
US20060106085A1 (en) * 2004-10-28 2006-05-18 Zeldis Jerome B Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
US20060128717A1 (en) * 2003-07-24 2006-06-15 Qun Sun Therapeutic agents useful for treating pain
US20060128738A1 (en) * 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
US20060134198A1 (en) * 2002-02-15 2006-06-22 Mark Tawa Pharmaceutical compositions with improved dissolution
WO2006066074A2 (en) 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
US20060147416A1 (en) * 2002-10-15 2006-07-06 Celgene Corporation Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
US20060165649A1 (en) * 2002-11-06 2006-07-27 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US20060173021A1 (en) * 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US20060173006A1 (en) * 2005-01-07 2006-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2006091871A1 (en) 2005-02-23 2006-08-31 Halozyme Therapeutics, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060194840A1 (en) * 2003-09-19 2006-08-31 David Gozal Method for treating snoring and sleep apnea with leukotriene antagonists
US20060199824A1 (en) * 2003-07-24 2006-09-07 Qun Sun Therapeutic agents useful for treating pain
US20060199819A1 (en) * 2000-03-31 2006-09-07 Celgene Corporation Inhibition of cyclooxygenase-2 activity
US20060199843A1 (en) * 2002-05-17 2006-09-07 Zeldis Jerome B Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
WO2006102426A2 (en) 2005-03-21 2006-09-28 Metabolex, Inc. Methods for avoiding edema in the treatment of metabolic, inflammatory, and cardiovascular disorders
EP1712232A1 (en) 1994-12-30 2006-10-18 Sepracor, Inc. Compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US20060235022A1 (en) * 2003-09-22 2006-10-19 Qun Sun Therapeutic agents useful for treating pain
US20060235055A1 (en) * 2003-07-03 2006-10-19 Kyle Donald J Therapeutic agents useful for treating pain
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US20060241117A1 (en) * 2003-09-22 2006-10-26 Qun Sun Therapeutic agents useful for treating pain
US20060247296A1 (en) * 2002-11-18 2006-11-02 Muller George W Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
WO2006119365A2 (en) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20060258669A1 (en) * 2003-08-01 2006-11-16 Kyle Donald J Therapeutic agents useful for treating pain
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20060286102A1 (en) * 2004-05-14 2006-12-21 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
WO2007013929A1 (en) 2005-07-22 2007-02-01 Amgen Inc. Aniline sulfonamide derivatives and their uses
US20070027159A1 (en) * 2003-06-12 2007-02-01 Kyle Donald J Therapeutic agents useful for treating pain
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US20070032500A1 (en) * 2003-12-30 2007-02-08 Qun Sun Therapeutic agents useful for treating pain
US20070037884A1 (en) * 2001-02-12 2007-02-15 Wyeth Novel succinate salt of O-desmethyl-venlafaxine
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
WO2007028073A2 (en) 2005-08-31 2007-03-08 Aryx Therapeutics, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007027527A2 (en) 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2007033112A1 (en) 2005-09-12 2007-03-22 Celgene Corporation Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2007037534A1 (en) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20070092585A1 (en) * 2005-10-14 2007-04-26 Skinner Michael K Cancer chemotherapy compositions comprising PI3K pathways modulators and triptolide
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US20070149731A1 (en) * 2001-10-12 2007-06-28 Monosolrx, Llc. PH modulated films for delivery of actives
US20070154527A1 (en) * 2001-10-12 2007-07-05 Monosoirx, Llc Topical film compositions for delivery of actives
US20070161081A1 (en) * 2005-11-10 2007-07-12 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
US20070172515A1 (en) * 2006-01-20 2007-07-26 Monosolrx, Llc Film bandage for mucosal administration of actives
WO2007087443A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
WO2007087442A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
WO2007089904A2 (en) 2006-01-31 2007-08-09 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
US20070190157A1 (en) * 2006-01-20 2007-08-16 Monosoirx, Llc. Film lined packaging and method of making same
US20070190127A1 (en) * 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US20070197823A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
US20070208057A1 (en) * 2003-11-06 2007-09-06 Zeldis Jerome B Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases
US20070208087A1 (en) * 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US7276364B1 (en) 1999-11-18 2007-10-02 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
US20070232671A1 (en) * 2006-03-13 2007-10-04 Given Bruce D Methods and compositions for treatment of diastolic heart failure
US20070244078A1 (en) * 2003-10-23 2007-10-18 Zeldis Jerome B Methods for Treatment, Modification and Management of Pain Using 1-Oxo-2-(2,6-Dioxopiperidin-3-yl)-4-Methylisoindoline
US20070254866A1 (en) * 2006-03-13 2007-11-01 Oana Cociorva Aminoquinolones as GSK-3 inhibitors
US20070254925A1 (en) * 2006-01-25 2007-11-01 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
US20070281003A1 (en) * 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
EP1867644A1 (en) 2003-07-24 2007-12-19 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
EP1867321A2 (en) * 2006-06-07 2007-12-19 Familplan Consulting Ltd. A pharmaceutical product adapted for oral transmucosal administration comprising a pharmaceutical agent
US20070299111A1 (en) * 2006-06-08 2007-12-27 Amgen Inc. Benzamide derivatives and uses related thereto
US20070299080A1 (en) * 2006-06-08 2007-12-27 Amgen Inc. Benzamide derivatives and uses related thereto
WO2007150002A2 (en) 2006-06-22 2007-12-27 Anadys Pharmaceuticals, Inc. PRODRUGS OF 5-AMINO-3-(3'-DEOXY-β-D-RIBOFURANOSYL)-THIAZOLO[4,5-d] PYRIMIDIN-2,7-DIONE
WO2007150001A1 (en) 2006-06-22 2007-12-27 Anadys Pharmaceuticals, Inc. Pyrro[1,2-b]pyridazinone compounds
US20070299033A1 (en) * 2004-06-17 2007-12-27 Trans Form Pharmaceuticals, Inc. Pharmaceutical Co-Crystal Compositions and Related Methods of Use
WO2008011406A2 (en) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
WO2008019065A1 (en) 2006-08-03 2008-02-14 Celgene Corporation Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
US20080045603A1 (en) * 2006-08-04 2008-02-21 John Devane Methods for treating at least one condition having MT1 receptor, 5HT2B receptor, and L-type calcium channel activity
WO2008021369A2 (en) 2006-08-14 2008-02-21 Chembridge Research Laboratories, Inc. Tricyclic compounds and its use as tyrosine kinase modulators
US20080044454A1 (en) * 2002-04-11 2008-02-21 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
WO2008027542A2 (en) 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US20080070928A1 (en) * 2003-12-29 2008-03-20 Katsumasa Nonoshita Novel 2-Heteroaryl-Substituted Benzimidazole Derivative
US20080075825A1 (en) * 2006-09-20 2008-03-27 Fuisz Richard C Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent
US20080076812A1 (en) * 2006-03-13 2008-03-27 Jinling Chen Formulations of sitaxsentan sodium
US20080081071A1 (en) * 2006-09-29 2008-04-03 Pradeep Sanghvi Film Embedded Packaging and Method of Making Same
WO2008039489A2 (en) 2006-09-26 2008-04-03 Celgene Corporation 5-substituted quinazolinone derivatives as antitumor agents
WO2008039520A2 (en) 2006-09-26 2008-04-03 Synta Pharmaceuticals Corp. Fused ring compounds for inflammation and immune-related uses
US7354948B2 (en) 2002-11-06 2008-04-08 Celgene Corporation Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US20080085921A1 (en) * 2004-01-07 2008-04-10 Aryx Therapeutics Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
WO2008044777A1 (en) 2006-10-06 2008-04-17 Banyu Pharmaceutical Co., Ltd. 2-pyridinecarboxamide derivative having gk-activating activity
WO2008049116A2 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008063504A2 (en) 2006-11-13 2008-05-29 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
WO2008066131A1 (en) 2006-12-01 2008-06-05 Banyu Pharmaceutical Co., Ltd. Novel phenyl-isoxazol-3-ol derivative
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20080138282A1 (en) * 2004-06-03 2008-06-12 The Trustees Of Columbia University In The City Of New York Radiolabeled Arylsulfonyl Compounds and Uses Thereof
US20080160099A1 (en) * 2004-11-10 2008-07-03 The Trustees Of Columbia University In The City Of New York Methods For Treating or Preventing a Vascular Disease
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20080188528A1 (en) * 2006-12-22 2008-08-07 Biediger Ronald J Modulators of C3a receptor and methods of use thereof
WO2008094476A1 (en) 2007-01-31 2008-08-07 Merck & Co., Inc. Substituted pyrano [2, 3 - b] pyridine derivatives as cannabinoid -1 receptor modulators
US20080188470A1 (en) * 2005-04-15 2008-08-07 Ranbaxy Laboratories Limited Oxazolidinone Derivatives as Antimicrobials
US20080199422A1 (en) * 2004-04-14 2008-08-21 Celgene Corporation Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
US20080206193A1 (en) * 2002-05-17 2008-08-28 Zeldis Jerome B Method for treatment and management of thyroid cancer using immunomodulatory compounds
US20080207569A1 (en) * 2007-02-28 2008-08-28 Spada Alfred P Methods for the treatment of liver diseases
US20080207605A1 (en) * 2007-02-28 2008-08-28 Spada Alfred P Combination therapy for the treatment of liver diseases
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
EP1967189A1 (en) 2004-02-18 2008-09-10 GPC Biotech AG Methods for treating resistant or refractory tumors
US20080221175A1 (en) * 2006-12-26 2008-09-11 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
US20080249148A1 (en) * 2007-03-09 2008-10-09 Wyeth Synthesis and characterization of polymorph form III 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
WO2008122965A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US20080261967A1 (en) * 2004-06-19 2008-10-23 John Cashman Modulators of Central Nervous System Neurotransmitters
US20080260809A1 (en) * 2002-04-11 2008-10-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7465800B2 (en) 2003-09-04 2008-12-16 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2002827A2 (en) 2001-12-05 2008-12-17 The Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US20080319020A1 (en) * 2005-11-21 2008-12-25 Purdue Pharma L.P. 4-Oxadiazolyl-Piperidine Compounds and Use Thereof
EP2011507A2 (en) 1999-09-17 2009-01-07 Novartis AG Pharmaceutical composition of nateglinide and another antidiabetic agent
US20090017024A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders
WO2009017831A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
WO2009017818A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Heterocycle-aryl compounds for inflammation and immune-related uses
US20090042987A1 (en) * 2007-07-06 2009-02-12 Michael Lionel Selley Treatment of neuropathic pain
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
US20090054530A1 (en) * 2004-05-07 2009-02-26 Nbty, Inc. Methods and Compositions that Enhance Bioavailability of Coenzyme-Q10
EP2030620A1 (en) 1999-05-07 2009-03-04 Wockhardt Limited (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
US20090062242A1 (en) * 2007-08-28 2009-03-05 Agi Therapeutics Plc Methods and compositions for treating gastrointestinal conditions
EP2033951A2 (en) 2002-02-01 2009-03-11 Euro-Celtique S.A. 2-Piperazine-pyridines useful for treating pain
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
WO2009042177A1 (en) 2007-09-26 2009-04-02 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
US7514466B2 (en) 2004-04-27 2009-04-07 Wyeth Purification of progesterone receptor modulators
US20090111818A1 (en) * 2005-07-06 2009-04-30 Sepracor Inc. Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
US20090111863A1 (en) * 2007-10-31 2009-04-30 Esposito Luke A Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US20090111846A1 (en) * 2006-02-03 2009-04-30 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders
US20090123452A1 (en) * 2006-07-05 2009-05-14 Madison Edwin L Protease screening methods and proteases identified thereby
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
WO2009063821A1 (en) 2007-11-12 2009-05-22 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy quinazoline derivative
US20090137590A1 (en) * 2007-07-19 2009-05-28 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
EP2065383A1 (en) 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Indazole compounds and methods of use thereof as protein kinase inhibitors
US20090149533A1 (en) * 2004-08-06 2009-06-11 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20090155211A1 (en) * 2002-09-27 2009-06-18 Wood Christopher B Methods and Compositions for the Treatment of Autoimmune Disorders Using Clofarabine
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP2074995A1 (en) 2002-03-20 2009-07-01 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US20090170868A1 (en) * 2007-04-27 2009-07-02 Purdue Pharma L. P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US20090170790A1 (en) * 2004-10-25 2009-07-02 Biswajit Das Ketolide derivatives as antibacterial agents
WO2009081782A1 (en) 2007-12-25 2009-07-02 Banyu Pharmaceutical Co., Ltd. N-pyrazole-2-pyridinecarboxamide derivative
WO2009089494A2 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2087891A2 (en) 2002-05-17 2009-08-12 Celgene Corporation Pharmaceutical compositions for treating lymphoma
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
EP2096107A1 (en) 2004-12-23 2009-09-02 GPC Biotech AG Derivatives of squaric acid with anti-proliferative activity
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US20090232796A1 (en) * 2008-02-20 2009-09-17 Corral Laura G Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
EP2112150A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Improved raf inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
US20090270404A1 (en) * 2008-03-31 2009-10-29 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
US20090297478A1 (en) * 2002-09-27 2009-12-03 Wood Christopher B Methods and Compositions for the Treatment of Lupus Using Clofarabine
WO2009147990A1 (en) 2008-06-02 2009-12-10 萬有製薬株式会社 Novel isoxazole derivative
US20090306014A1 (en) * 2005-12-28 2009-12-10 Acidophil Llc C-10 carbamates of taxanes
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20100004304A1 (en) * 2004-03-16 2010-01-07 Kohn Leonard D Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
US20100015220A1 (en) * 2008-05-20 2010-01-21 Wetterau John R Niacin and nsaid combination therapy
US20100015698A1 (en) * 2002-12-16 2010-01-21 Halozyme, Inc. Human Chondroitinase Glycoprotein (CHASEGP), Process for Preparing the Same, and Pharmaceutical Compositions Comprising Thereof
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
US20100022519A1 (en) * 2007-01-16 2010-01-28 Brown Kevin C Heterocyclic-substituted piperidine compounds and the uses thereof
US20100021526A1 (en) * 2001-10-12 2010-01-28 Monosol Rx, Llc Ph modulated films for delivery of actives
WO2010014229A1 (en) 2008-07-30 2010-02-04 Purdue Pharma L.P. Buprenorphine analogs
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7671093B2 (en) 2004-05-28 2010-03-02 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
US20100055093A1 (en) * 2006-06-12 2010-03-04 Receptor Biologix Inc. Pan-cell surface receptor-specific therapeutics
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US20100069437A1 (en) * 2002-11-18 2010-03-18 Purdue Pharma L.P. Therapeutic agents useful for treating pain
WO2010042834A1 (en) 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20100120862A1 (en) * 2008-10-24 2010-05-13 Laykea Tafesse Monocyclic compounds and their use as trpv1 ligands
WO2010054001A2 (en) 2008-11-04 2010-05-14 University Of Kentucky Research Foundation D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof
US20100130511A1 (en) * 2006-12-28 2010-05-27 Metabolex, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US20100130510A1 (en) * 2008-10-01 2010-05-27 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US20100130499A1 (en) * 2008-10-24 2010-05-27 Laykea Tafesse Bicycloheteroaryl compounds and their use as trpv1 ligands
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US20100130552A1 (en) * 2007-04-27 2010-05-27 Laykea Tafesse Therapeutic Agents Useful for Treating Pain
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
US20100137306A1 (en) * 2008-10-24 2010-06-03 Laykea Tafesse Heterocyclic trpv1 receptor ligands
US20100143469A1 (en) * 2006-10-09 2010-06-10 Paul Bosse Pharmaceutical compositions
US20100160350A1 (en) * 2007-05-29 2010-06-24 Kluge Arthur F Pyrazolopyrimidinone kinase inhibitor
WO2010075064A1 (en) 2008-12-16 2010-07-01 Sepracor Inc. Triple reuptake inhibitors and methods of their use
WO2010075280A2 (en) 2008-12-22 2010-07-01 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds
WO2010075255A2 (en) 2008-12-22 2010-07-01 Sloan-Kettering Institute For Cancer Research Methods for treating or preventing cancer and neurodegenerative diseases
WO2010076329A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
WO2010077297A1 (en) 2008-12-09 2010-07-08 Halozyme, Inc. Extended soluble ph20 polypeptides and uses thereof
EP2210606A2 (en) 2002-11-06 2010-07-28 Celgene Corporation Methods Of Using And Compositions Comprising Immunomodulatory Compounds For The Treatment And Management Of Myeloproliferative Diseases
US20100190831A1 (en) * 2008-12-18 2010-07-29 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
US20100190728A1 (en) * 2004-05-28 2010-07-29 Human Biomolecular Research Institute Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents
US20100197772A1 (en) * 2007-07-18 2010-08-05 Andrea Califano Tissue-Specific MicroRNAs and Compositions and Uses Thereof
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US20100197570A1 (en) * 2007-06-05 2010-08-05 Arizona Board of Regents ,a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz Cyclodepsipeptides with Antineoplastic Activity and Methods of Using to Inhibit Cancer and Microbial Growth
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
WO2010093746A1 (en) 2009-02-11 2010-08-19 Hope Medical Enterprise, Inc. D.B.A. Hope Pharmaceuticals Sodium nitrite-containing pharmaceutical compositions
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
WO2010093588A1 (en) 2009-02-10 2010-08-19 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
WO2010093425A1 (en) 2009-02-11 2010-08-19 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2010095767A1 (en) 2009-02-23 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Pyrimidin-4(3h)-one derivatives
US20100215738A1 (en) * 2009-02-24 2010-08-26 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US20100216726A1 (en) * 2007-08-31 2010-08-26 Purdue Pharma L.P. Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
US20100216827A1 (en) * 2008-10-21 2010-08-26 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
WO2010099379A1 (en) 2009-02-27 2010-09-02 Ambit Biosciences Corporation Jak kinase modulating quinazoline derivatives and methods of use thereof
US20100222394A1 (en) * 2007-09-28 2010-09-02 Kenichi Asakawa Method for producing pyrazol-3-yl-benzamide derivative
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2010102262A1 (en) 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
WO2010105016A1 (en) 2009-03-11 2010-09-16 Ambit Biosciences Corp. Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
WO2010104195A1 (en) 2009-03-11 2010-09-16 Banyu Pharmaceutical Co.,Ltd. Novel isoindolin-1-one derivative
US20100234367A1 (en) * 2009-03-11 2010-09-16 Kyorin Pharmaceuticals Co. Ltd 7-cycloalkylaminoquinolones as gsk-3 inhibitors
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
WO2010110685A2 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimddinyl and 1,3,5-triazinyl benzimtoazole sulfonamides and their use in cancer therapy
US20100260778A1 (en) * 2005-09-20 2010-10-14 Yuan-Ping Pang Small-molecule botulinum toxin inhibitors
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
WO2010123930A2 (en) 2009-04-20 2010-10-28 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US20100278779A1 (en) * 2002-10-15 2010-11-04 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
WO2010127452A1 (en) 2009-05-04 2010-11-11 The Royal Institution For The Advancement Of Learning/Mcgill University 5-oxo-ete receptor antagonist compounds
US20100311787A1 (en) * 2004-09-21 2010-12-09 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2010144571A1 (en) 2009-06-10 2010-12-16 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
WO2011005841A1 (en) 2009-07-08 2011-01-13 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
WO2011005119A1 (en) 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
US20110009463A1 (en) * 2007-10-17 2011-01-13 Yuri Karl Petersson Geranylgeranyl transferase inhibitors and methods of making and using the same
WO2011009961A1 (en) 2009-07-24 2011-01-27 Virologik Gmbh Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
WO2011014775A1 (en) 2009-07-31 2011-02-03 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US20110033541A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
WO2011018504A2 (en) 2009-08-12 2011-02-17 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
WO2011022473A1 (en) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
EP2289497A1 (en) 2005-11-10 2011-03-02 Circ Pharma Research and Development Limited Once-daily administration of central nervous system drugs
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
WO2011029099A1 (en) 2009-09-04 2011-03-10 United Paragon Associates Inc. Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
EP2295416A2 (en) 2004-11-18 2011-03-16 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2011031816A2 (en) 2009-09-11 2011-03-17 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
US20110065660A1 (en) * 2009-04-20 2011-03-17 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
EP2298770A1 (en) 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011042482A1 (en) 2009-10-06 2011-04-14 Green Molecular Polyphenols for use in the treatment of cancer
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2011049946A1 (en) 2009-10-19 2011-04-28 Synta Pharmaceuticals Corp. Combination cancer therapy with hsp90 inhibitory compounds
US20110104144A1 (en) * 2005-12-29 2011-05-05 Celgene Corporation Methods for treating cutaneous lupus using aminoisoindoline compounds
US20110105497A1 (en) * 2009-10-26 2011-05-05 Anantha Sudhakar Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
US20110118245A1 (en) * 2008-03-17 2011-05-19 Sunny Abraham Raf kinase modulator compounds and methods of use thereof
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011063102A1 (en) 2009-11-19 2011-05-26 Celgene Corporation Apremilast for the treatment of sarcoidosis
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
WO2011070364A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
US20110152280A1 (en) * 2009-12-23 2011-06-23 Map Pharmaceuticals, Inc. Novel ergoline analogs
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2339328A2 (en) 2002-12-30 2011-06-29 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2011079091A1 (en) 2009-12-22 2011-06-30 Celgene Corporation (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
WO2011082289A1 (en) 2009-12-30 2011-07-07 Scynexis Inc. Cyclosporine analogues
US20110172273A1 (en) * 2002-10-15 2011-07-14 Zeldis Jerome B Methods of treating myelodysplastic syndromes using lenalidomide
US20110172219A1 (en) * 2007-09-11 2011-07-14 Bei Li Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
US20110178090A1 (en) * 2008-07-21 2011-07-21 Fuchino Kouki Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
US20110195978A1 (en) * 2008-10-10 2011-08-11 Purdue Research Foundation Compounds for treatment of alzheimer's disease
WO2011097300A1 (en) 2010-02-02 2011-08-11 Argusina, Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US20110201594A1 (en) * 2006-10-16 2011-08-18 Krisna Murthi Pyrido [2,3-d] pyrimidines and their use as kinase inhibitors
WO2011100380A1 (en) 2010-02-11 2011-08-18 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011109345A1 (en) 2010-03-02 2011-09-09 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
US20110223157A1 (en) * 2010-03-12 2011-09-15 Schafer Peter H Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
WO2011116161A2 (en) 2010-03-17 2011-09-22 Axikin Pharmaceuticals Inc. Arylsulfonamide ccr3 antagonists
US20110230505A1 (en) * 2008-11-20 2011-09-22 Purdue Research Foundation Quinazoline inhibitors of bace 1 and methods of using
WO2011127019A2 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
WO2011127070A2 (en) 2010-04-05 2011-10-13 Mannkind Corporation IRE-1α INHIBITORS
WO2011127232A2 (en) 2010-04-08 2011-10-13 Emory University Substituted androst-4-ene diones
WO2011133521A2 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2011146803A1 (en) 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
WO2011150183A1 (en) 2010-05-28 2011-12-01 Ge Healthcare Limited Radiolabeled compounds and methods thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011149824A1 (en) 2010-05-24 2011-12-01 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2011153199A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
WO2011153197A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
WO2011156321A1 (en) 2010-06-07 2011-12-15 Novomedix, Llc Furanyl compounds and the use thereof
WO2011159297A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
WO2012012370A1 (en) 2010-07-19 2012-01-26 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
WO2012025217A1 (en) 2010-08-24 2012-03-01 Algiax Pharmaceuticals Gmbh Novel use of leflunomide and malononitrilamides
WO2012030894A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
WO2012030913A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030885A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030924A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2012037072A1 (en) 2010-09-13 2012-03-22 Synta Pharmaceuticals Corporation Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
EP2433634A2 (en) 2004-09-17 2012-03-28 The Whitehead Institute for Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012051090A1 (en) 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
WO2012055567A2 (en) 2010-10-29 2012-05-03 Algiax Pharmaceuticals Gmbh Use of malononitrilamides in neuropathic pain
WO2012064808A1 (en) 2010-11-09 2012-05-18 Synta Pharmaceuticals Corp Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2012069658A2 (en) 2010-11-25 2012-05-31 Sigmoid Pharma Limited Immunomodulatory compositions
WO2012078757A2 (en) 2010-12-08 2012-06-14 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
WO2012083017A2 (en) 2010-12-16 2012-06-21 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2012085648A1 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
EP2471518A2 (en) 2009-05-18 2012-07-04 Sigmoid Pharma Limited Composition comprising oil drops
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
EP2476690A1 (en) 2008-07-02 2012-07-18 IDENIX Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2012096884A1 (en) 2011-01-10 2012-07-19 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
WO2012096919A1 (en) 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
WO2012097000A1 (en) 2011-01-10 2012-07-19 Pingda Ren Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012096929A2 (en) 2011-01-11 2012-07-19 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012116061A1 (en) 2011-02-23 2012-08-30 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
WO2012116247A1 (en) 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
WO2012115723A1 (en) 2011-02-25 2012-08-30 Medtronic, Inc. Emergency mode switching for non-pacing modes
WO2012121988A2 (en) 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
EP2500337A2 (en) 2007-02-21 2012-09-19 Sepracor Inc. Solid form comprising (-) o-desmethylvenlafaxine and uses thereof
WO2012125475A1 (en) 2011-03-11 2012-09-20 Celgene Corporation Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
WO2012123406A1 (en) 2011-03-17 2012-09-20 Algiax Pharmaceuticals Gmbh Novel use of imidazotriazinones
WO2012125438A1 (en) 2011-03-11 2012-09-20 Celgene Corporation Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2012123353A1 (en) 2011-03-17 2012-09-20 Algiax Pharmaceuticals Gmbh Novel use of benzofuranylsulfonates
EP2502921A1 (en) 2009-04-22 2012-09-26 Axikin Pharmaceuticals, Inc. Arylsulfonamide CCR3 antagonists
WO2012129237A2 (en) 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd
EP2505200A1 (en) 2004-03-22 2012-10-03 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
WO2012135166A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135581A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012135175A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135160A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
WO2012141796A2 (en) 2011-02-24 2012-10-18 Synta Pharmaceuticals Corp. Prostate cancer therapy with hsp90 inhibitory compounds
EP2514740A1 (en) 2007-03-15 2012-10-24 Auspex Pharmaceuticals, Inc. Deuterated O-desmethylvenlafaxines with serotoninergic and/or norepinephrinergic activity
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2012149299A2 (en) 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2012149251A1 (en) 2011-04-28 2012-11-01 Celgene Corporation Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
EP2520561A1 (en) 2007-06-08 2012-11-07 MannKind Corporation IRE-1A Inhibitors
WO2012151355A1 (en) 2011-05-03 2012-11-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2012151474A2 (en) 2011-05-04 2012-11-08 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2012158271A1 (en) 2011-04-06 2012-11-22 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds as antiviral agents
WO2012162372A1 (en) 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
WO2012170536A1 (en) 2011-06-07 2012-12-13 Anadys Pharmaceuticals, Inc. [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
WO2012169934A1 (en) 2011-06-08 2012-12-13 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Novel kinase inhibitors
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
WO2012176061A1 (en) 2011-06-22 2012-12-27 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
WO2013006864A2 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013014274A1 (en) 2011-07-28 2013-01-31 Ge Healthcare Limited 5ht1a antagonist useful for in vivo imaging
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
WO2013024040A2 (en) 2011-08-12 2013-02-21 B.S.R.C. Alexander Fleming Tnf superfamily trimerization inhibitors
EP2561872A1 (en) 2004-12-17 2013-02-27 Anadys Pharmaceuticals, Inc. 3, 5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof
WO2013028505A1 (en) 2011-08-19 2013-02-28 Synta Pharmaceuticals Corp. Combination cancer therapy of hsp90 inhibitor with antimetabolite
WO2013028880A1 (en) 2011-08-23 2013-02-28 Cornerstone Therapeutics Inc. Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP2572712A2 (en) 2007-06-01 2013-03-27 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2013043967A1 (en) 2011-09-23 2013-03-28 Celgene Corporation Romidepsin and 5 - azacitidine for use in treating lymphoma
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013049093A1 (en) 2011-09-26 2013-04-04 Celgene Corporation Combination therapy for chemoresistant cancers
WO2013052776A1 (en) 2011-10-07 2013-04-11 Cedars-Sinai Medical Center Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
WO2013055985A1 (en) 2011-10-12 2013-04-18 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
WO2013056070A2 (en) 2011-10-14 2013-04-18 Ambit Biosciences Corporation Heterocyclic compounds and methods of use thereof
EP2586428A1 (en) 2007-04-26 2013-05-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013067043A1 (en) 2011-11-01 2013-05-10 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013080036A1 (en) 2011-12-01 2013-06-06 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof
WO2013084060A1 (en) 2011-12-08 2013-06-13 Purdue Pharma L.P. Quaternized buprenorphine analogs
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
WO2013101926A1 (en) 2011-12-28 2013-07-04 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
WO2013103811A2 (en) 2012-01-05 2013-07-11 Boston Medical Center Corporation Slit-robo signaling for diagnosis and treatment of kidney disease
WO2013103919A2 (en) 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
WO2013103384A1 (en) 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
EP2617704A1 (en) 2007-05-31 2013-07-24 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP2617423A1 (en) 2006-10-19 2013-07-24 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
WO2013119895A1 (en) 2012-02-08 2013-08-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2013126394A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
WO2013133708A1 (en) 2012-03-07 2013-09-12 Stichting Vu-Vumc Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
WO2013138617A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
WO2013142114A1 (en) 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
WO2013142380A1 (en) 2012-03-22 2013-09-26 The Regents Of The University Of California Oncovector nucleic acid molecules and methods of use
WO2013148857A1 (en) 2012-03-28 2013-10-03 Synta Pharmaceuticals Corp. Triazole derivatives as hsp90 inhibitors
WO2013148864A1 (en) 2012-03-27 2013-10-03 Andrei Gudkov Curaxins for use in treating breast cancer and method for identifying patients likely to respond
WO2013151774A1 (en) 2012-04-04 2013-10-10 Halozyme, Inc. Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
WO2013152206A1 (en) 2012-04-04 2013-10-10 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
WO2013154878A1 (en) 2012-04-10 2013-10-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013156232A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of benzofuranylsulfonates in neuropathic pain
WO2013156231A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of imidazotriazinones in neuropathic pain
WO2013156850A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
WO2013163758A1 (en) 2012-05-01 2013-11-07 Boyd Shelley Romayne Methods for treating and diagnosing blinding eye diseases
EP2662090A1 (en) 2008-04-14 2013-11-13 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
WO2013167963A1 (en) 2012-05-11 2013-11-14 Purdue Pharma L.P. Benzomorphan compounds as opioid receptors modulators
WO2013170159A1 (en) 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
US8592445B2 (en) 2011-12-19 2013-11-26 Map Pharmaceuticals, Inc. Iso-ergoline derivatives
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013177219A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
US8604035B2 (en) 2011-06-23 2013-12-10 Map Pharmaceuticals, Inc. Fluoroergoline analogs
WO2014006215A1 (en) 2012-07-05 2014-01-09 Sigmoid Pharma Limited Hydrogel vaccine formulations
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2687213A1 (en) 2008-03-27 2014-01-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US8637087B2 (en) 2004-12-13 2014-01-28 Jb Therapeutics Inc. Treatment of interstitial cystitis using (6aR, 10aR)-Δ8-tetrahydrocannabinol-11-OIC acids
WO2014020405A1 (en) 2012-07-30 2014-02-06 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
EP2695616A1 (en) 2008-03-27 2014-02-12 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
WO2014025960A1 (en) 2012-08-09 2014-02-13 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
WO2014030053A1 (en) 2012-08-20 2014-02-27 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
WO2014033530A1 (en) 2012-08-27 2014-03-06 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
WO2014039748A1 (en) 2012-09-07 2014-03-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
WO2014039960A1 (en) 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
WO2014059251A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
WO2014058801A1 (en) 2012-10-08 2014-04-17 Idenix Pharmaceuticals, Inc. 2'-chloro nucleoside analogs for hcv infection
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US8710236B2 (en) 2007-02-09 2014-04-29 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
EP2727908A2 (en) 2009-04-22 2014-05-07 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
WO2014071109A1 (en) 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014074765A2 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
WO2014074846A1 (en) 2012-11-09 2014-05-15 Celgene Corporation Methods for the treatment of bone loss
WO2014072809A2 (en) 2012-11-09 2014-05-15 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8728522B2 (en) 2009-07-08 2014-05-20 Charleston Laboratories, Inc. Pharmaceutical compositions for treating or preventing pain
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
WO2014085633A1 (en) 2012-11-30 2014-06-05 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
WO2014085284A1 (en) 2012-11-29 2014-06-05 Sunovion Pharmaceuticals Inc. Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
WO2014087226A1 (en) 2012-12-07 2014-06-12 Purdue Pharma L.P. Buprenorphine analogs as opiod receptor modulators
WO2014093189A1 (en) 2012-12-10 2014-06-19 Merck Sharp & Dohme Corp. Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
WO2014091297A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Spirocyclic morphinans and their use
WO2014091298A2 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
WO2014091295A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Pyridonemorphinan analogs and biological activity on opioid receptors
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
EP2749559A1 (en) 2008-05-30 2014-07-02 Celgene Corporation 5-substituted isoindoline compounds
EP2749554A2 (en) 2009-04-22 2014-07-02 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
WO2014102590A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014102587A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. 7,8-cyclicmorphinan analogs
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
WO2014102593A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
WO2014106238A1 (en) 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
WO2014102589A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
WO2014107617A1 (en) 2013-01-05 2014-07-10 Elcelyx Therapeutics, Inc. Delayed-release composition comprising biguanide
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
WO2014110558A1 (en) 2013-01-14 2014-07-17 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014110305A1 (en) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamins c and k for treating polycystic diseases
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US8796226B2 (en) 2010-01-04 2014-08-05 Mapi Pharma Ltd. Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
WO2014118618A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
WO2014120936A2 (en) 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US8815906B2 (en) 2008-03-19 2014-08-26 Chembridge Corporation Tyrosine kinase inhibitors
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014140784A2 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Buprenorphine analogs
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014151180A1 (en) 2013-03-14 2014-09-25 Celgene Corporation Treatment of psoriatic arthritis using apremilast
WO2014165482A1 (en) 2013-04-02 2014-10-09 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
US8859780B2 (en) 2011-12-28 2014-10-14 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
US8859590B2 (en) 2008-12-05 2014-10-14 Purdue Research Foundation Inhibitors of BACE1 and methods for treating Alzheimer's disease
US8895743B2 (en) 2012-12-21 2014-11-25 Map Pharmaceuticals, Inc. Methysergide derivatives
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
US8907103B2 (en) 2008-08-13 2014-12-09 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2014210596A1 (en) 2013-06-28 2014-12-31 Purdue Pharma L.P. Treating an arrhythmia with an opioid antagonist
WO2015003167A1 (en) 2013-07-03 2015-01-08 Halozyme, Inc. Thermally stable ph20 hyaluronidase variants and uses thereof
WO2015009534A2 (en) 2013-07-16 2015-01-22 Allergan, Inc. Hcn inhibitors affecting ganglion cell function and visual function
US8940927B2 (en) 2007-08-13 2015-01-27 Metabasis Therapeutics, Inc. Activators of glucokinase
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US8969583B2 (en) 2011-12-28 2015-03-03 Allergan, Inc. 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
US8974826B2 (en) 2010-06-10 2015-03-10 Monosol Rx, Llc Nanoparticle film delivery systems
EP2851064A2 (en) 2006-07-11 2015-03-25 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
EP2851070A1 (en) 2010-01-05 2015-03-25 Celgene Corporation A combination of lenalidomide and artesunate/artemisone for treating cancer
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015042111A1 (en) 2013-09-18 2015-03-26 Axikin Pharmaceuticals, Inc. Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015044759A1 (en) 2013-09-24 2015-04-02 Purdue Pharma L.P. Treatment of burn pain by trpv1 modulators
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
EP2865381A1 (en) 2006-05-18 2015-04-29 Pharmacyclics, Inc. ITK inhibitors for treating blood cell malignancies
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
WO2015067762A1 (en) 2013-11-08 2015-05-14 Sigmoid Pharma Limited Formulations comprising cyclosporin a
US9034870B2 (en) 2012-07-13 2015-05-19 Purdue Research Foundation Azaindenoisoquinoline topoisomerase I inhibitors
WO2015081133A2 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
WO2015081297A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US9062057B2 (en) 2010-03-19 2015-06-23 Purdue Research Foundation CCR5 antagonists for treating HIV
WO2015095419A1 (en) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
WO2015102682A1 (en) 2013-12-30 2015-07-09 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2015112568A1 (en) 2014-01-24 2015-07-30 Celgene Corporation Methods for the treatment of obesity using apremilast
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
EP2910551A1 (en) 2003-04-11 2015-08-26 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US9120815B2 (en) 2010-02-05 2015-09-01 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015143161A1 (en) 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015140081A1 (en) 2014-03-18 2015-09-24 Algiax Pharmaceuticals Gmbh 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
EP2933002A1 (en) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
EP2937083A1 (en) 2009-12-04 2015-10-28 Sunovion Pharmaceuticals Inc. Formulations, salts and polymorphs of transnorsertraline and uses thereof
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
WO2015175773A1 (en) 2014-05-15 2015-11-19 Celgene Corporation Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
WO2015175381A1 (en) 2014-05-12 2015-11-19 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitors
EP2947100A1 (en) 2009-01-06 2015-11-25 Curelon LLC Oral compositions for the treatment or the prevention of infections by E. Coli
WO2015176780A1 (en) 2014-05-23 2015-11-26 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
US9200114B2 (en) 2011-04-21 2015-12-01 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
WO2015181624A2 (en) 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
EP2959917A2 (en) 2007-10-19 2015-12-30 The Regents of The University of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
WO2016007848A1 (en) 2014-07-11 2016-01-14 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP2974724A1 (en) 2009-02-09 2016-01-20 Sunovion Pharmaceuticals Inc. Pyrrolidine triple reuptake inhibitors
US9241924B2 (en) 2010-06-23 2016-01-26 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US9249147B2 (en) 2008-03-19 2016-02-02 Chembridge Corporation Tyrosine kinase inhibitors
EP2985281A2 (en) 2008-10-29 2016-02-17 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
WO2016033555A1 (en) 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
US9290463B2 (en) 2010-05-05 2016-03-22 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
US9296747B1 (en) 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016061286A2 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2016065028A1 (en) 2014-10-21 2016-04-28 Ariad Pharmaceuticals, Inc. Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
WO2016106309A1 (en) 2014-12-23 2016-06-30 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
EP3042654A1 (en) 2011-01-20 2016-07-13 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
WO2016130502A1 (en) 2015-02-09 2016-08-18 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
US9421178B2 (en) 2011-12-02 2016-08-23 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3064217A1 (en) 2009-01-06 2016-09-07 Curelon LLC Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections
WO2016142877A1 (en) 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
US9447401B2 (en) 2011-12-30 2016-09-20 Halozyme, Inc. PH20 polypeptide variants, formulations and uses thereof
WO2016164336A1 (en) 2015-04-06 2016-10-13 Celgene Corporation Hepatocellular carcinoma treatment using a combination of cc 122 and sorafenib
US9486463B2 (en) 2010-10-19 2016-11-08 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
WO2016189055A1 (en) 2015-05-27 2016-12-01 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
WO2016202721A1 (en) 2015-06-16 2016-12-22 F. Hoffmann-La Roche Ag Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
WO2016210180A2 (en) 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2017017631A2 (en) 2015-07-28 2017-02-02 Vyome Biosciences Pvt. Ltd. Antibacterial therapeutics and prophylactics
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
US9611465B2 (en) 2009-05-25 2017-04-04 Celgene Corporation Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell
WO2017059385A1 (en) 2015-09-30 2017-04-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US9617607B2 (en) 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
WO2017064657A1 (en) 2015-10-16 2017-04-20 Invictus Oncology Pvt. Ltd. Fluorescent anticancer platinum drugs
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075340A1 (en) 2015-10-30 2017-05-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
US9642836B2 (en) 2011-01-14 2017-05-09 Celgene Corporation Isotopologues of isoindole derivatives
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
US9676776B2 (en) 2015-01-20 2017-06-13 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
EP3178465A1 (en) 2010-12-06 2017-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
WO2017117478A1 (en) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
US9725465B2 (en) 2013-08-30 2017-08-08 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
WO2017134305A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Bispecific signaling agents and uses thereof
US9732038B2 (en) 2012-06-14 2017-08-15 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
US9750757B2 (en) 2013-10-29 2017-09-05 Thomas Jefferson University Methods of prevention or treatment for pathologic thrombosis or inflammation
US9757355B2 (en) 2011-01-10 2017-09-12 Celgene Corporation Oral dosage forms of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
WO2017153402A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US9775852B2 (en) 2013-03-15 2017-10-03 The Regents Of The University Of California Acyclic nucleoside phosphonate diesters
US9775889B2 (en) 2008-03-06 2017-10-03 Halozyme, Inc. Methods of treatment of cellulite
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US9801884B2 (en) 2014-09-15 2017-10-31 The Regents Of The University Of California Nucleotide analogs
WO2017190086A1 (en) 2016-04-29 2017-11-02 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
EP3241833A1 (en) 2010-10-18 2017-11-08 Cerenis Therapeutics Holding SA Compounds, compositions and methods useful for cholesterol mobilisation
WO2017192858A1 (en) 2016-05-04 2017-11-09 Purdue Pharma L.P. Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
WO2017194782A2 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
WO2017200902A1 (en) 2016-05-16 2017-11-23 Biotheryx, Inc. Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
EP3252057A2 (en) 2009-12-04 2017-12-06 Sunovion Pharmaceuticals Inc. Multicyclic compounds and methods of use thereof
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9857359B2 (en) 2012-06-29 2018-01-02 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US9867828B2 (en) 2005-03-11 2018-01-16 Aminopterin Llc Aminopterin dosage forms
WO2018015861A1 (en) 2016-07-18 2018-01-25 Pharmena S.A. 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein
WO2018020418A1 (en) 2016-07-26 2018-02-01 Purdue Pharma L.P. Treatment and prevention of sleep disorders
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
WO2018049080A1 (en) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
US9938254B2 (en) 2016-01-08 2018-04-10 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018069312A1 (en) 2016-10-11 2018-04-19 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
EP3318561A1 (en) 2010-05-26 2018-05-09 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2018089427A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
WO2018102673A1 (en) 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
US10001483B2 (en) 2015-06-26 2018-06-19 Celgene Corporation Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
US10034833B2 (en) 2016-03-14 2018-07-31 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3339546A (en) * 1963-12-13 1967-09-05 Squibb & Sons Inc Bandage for adhering to moist surfaces
US3429308A (en) * 1964-04-30 1969-02-25 Higham Stanley Russell Method for administering drugs from a vehicle adhering by suction to the parabuccal cavity mucous membrane

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3339546A (en) * 1963-12-13 1967-09-05 Squibb & Sons Inc Bandage for adhering to moist surfaces
US3429308A (en) * 1964-04-30 1969-02-25 Higham Stanley Russell Method for administering drugs from a vehicle adhering by suction to the parabuccal cavity mucous membrane

Cited By (1353)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US4292299A (en) * 1978-11-06 1981-09-29 Teijin Limited Slow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
DE3237945A1 (en) * 1981-10-20 1983-05-05 Sandoz Ag Pharmaceutical compositions with sustained release
US5910304A (en) * 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4859667A (en) * 1983-01-21 1989-08-22 Merck Frosst Canada, Inc. Pharmaceutical compositions of phenothiazone derivatives and analogs
US4667032A (en) * 1983-01-21 1987-05-19 Merck Frosst Canada, Inc. Phenothiazone derivatives and analogs
US4892736A (en) * 1983-10-07 1990-01-09 The Forsyth Dental Infirmary For Children Intra-pocket drug delivery devices for treatment of periodontal diseases
EP0206741A2 (en) 1985-06-18 1986-12-30 Merck Frosst Canada Inc. Leukotriene antagonists
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
EP0239306A2 (en) 1986-03-27 1987-09-30 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
US4889720A (en) * 1986-09-01 1989-12-26 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form for use with tissues of the oral cavity
US5830456A (en) * 1986-11-06 1998-11-03 The Texas A&M University System Treatment of viral disease with oral interferon-α
US5019382A (en) * 1986-11-06 1991-05-28 The Texas A&M University System Treatment of immuno-resistant disease with low-dose interferon
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
US5250028A (en) * 1989-02-15 1993-10-05 Alza Corporation Intravenous system for delivering a beneficial agent using permeability enhancers
US5045059A (en) * 1989-02-15 1991-09-03 Alza Corporation Intravenous system for delivering a beneficial agent
US5160320A (en) * 1989-02-15 1992-11-03 Alza Corporation Intravenous system for delivering a beneficial agent
US4985016A (en) * 1989-02-15 1991-01-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4969871A (en) * 1989-02-15 1990-11-13 Alza Corporation Intravenous system for delivering a beneficial agent
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5173302A (en) * 1990-09-28 1992-12-22 Medtronic, Inc. Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs
US5648396A (en) * 1991-02-04 1997-07-15 Sepracor Inc. Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
EP1712232A1 (en) 1994-12-30 2006-10-18 Sepracor, Inc. Compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US7329761B2 (en) 1994-12-30 2008-02-12 Celgene Corporation Substituted imides
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US20050090516A1 (en) * 1994-12-30 2005-04-28 Muller George W. Novel substituted imides
US7214684B2 (en) 1994-12-30 2007-05-08 Sepracor Inc. Methods for the treatment of allergic rhinitis
US20020090394A1 (en) * 1995-07-20 2002-07-11 Smithkline Beecham Plc Paroxetine controlled release compositions
US7229640B2 (en) 1995-07-20 2007-06-12 Smithkline Beecham P.L.C. Paroxetine controlled release compositions
US6858589B2 (en) 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
US7019030B2 (en) 1996-08-12 2006-03-28 Celgene Corporation Immunotherapeutic agents
US20040019106A1 (en) * 1996-08-12 2004-01-29 Muller George W. Novel immunotherapeutic agents
US20030045726A1 (en) * 1996-08-12 2003-03-06 Muller George W. Novel immunotherapeutic agents
US5962464A (en) * 1997-02-11 1999-10-05 Sepracor Inc. Methods and compositions for treating allergic asthma using descarboethoxyloratadine
US6054463A (en) * 1997-02-11 2000-04-25 Sepracor Inc. Methods for treating dermatitis using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6664397B1 (en) 1997-03-07 2003-12-16 Vernalis Research Limited Use of (+)mefloquine for the treatment of malaria
US6197788B1 (en) 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
US20030064988A1 (en) * 1998-01-21 2003-04-03 Morgan Phillip Frederick Pharmaceutically active morpholinol
US20060189612A1 (en) * 1998-01-21 2006-08-24 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US7098206B2 (en) 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US20030032643A1 (en) * 1998-01-22 2003-02-13 Ascher John A. Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6495605B2 (en) 1998-01-29 2002-12-17 Sepracor Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion
US6277887B1 (en) 1998-01-29 2001-08-21 Sepracor, Inc. Methods for treating Parkinson's disease using optically pure (−)-bupropion
US6451860B1 (en) 1998-01-29 2002-09-17 Sepracor, Inc. Methods for treating depression and other disorders using optically pure (−)-bupropion
US6110973A (en) * 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US20030022942A1 (en) * 1998-01-29 2003-01-30 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion
US6369113B2 (en) 1998-01-29 2002-04-09 Sepracor, Inc. Method for treating depression using optically pure (−)-bupropion
US6458374B1 (en) 1998-01-29 2002-10-01 Sepracor, Inc. Methods and compositions for treating chronic disorders using optically pure (+)-bupropion
US6559165B1 (en) 1998-06-15 2003-05-06 Sepracor, Inc. Methods for treating bulimia using optically pure (−) norcisapride
US20050154018A1 (en) * 1998-06-15 2005-07-14 Sepracor Inc. Method for treating and preventing disorders using optically pure (+) norcisapride
US7064138B2 (en) 1998-06-15 2006-06-20 Sepracor Inc. Methods for treating irritable bowel syndrome using optically pure (-) norcisapride
US6835740B2 (en) 1998-06-15 2004-12-28 Sepracor Inc. Methods for treating sleep apnea and sleep induced apnea using optically pure (+) norcisapride
US6048879A (en) * 1998-06-15 2000-04-11 Sepracor Inc. Methods for treating apnea, apnea disorders, bulimia, and other disorders using optically pure (+) norcisapride
US6369079B1 (en) 1998-06-15 2002-04-09 Sepracor, Inc. Methods for treating irritable bowel syndrome using optically pure (+) norcisapride
US20040116534A1 (en) * 1998-08-24 2004-06-17 Sepracor, Inc. Methods of treating and preventing narcolepsy using enantiomerically pure (s)-didesmethylsibutramine
US20030195261A1 (en) * 1998-08-24 2003-10-16 Sepracor Inc. Methods of treating or preventing erectile dysfunction
US20040092481A1 (en) * 1998-08-24 2004-05-13 Sepracor, Inc. Methods of treating and preventing depression using didesmethylsibutramine
US20040162355A1 (en) * 1998-08-24 2004-08-19 Sepracor Inc. Methods of treating and preventing cerebral function disorders using sibutramine metabolites
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6538034B2 (en) 1998-08-24 2003-03-25 Thomas P. Jerussi Methods of treating or preventing weight gain, obesity, and related disorders
US7071234B2 (en) 1998-08-24 2006-07-04 Sepracor Inc. Methods of treating or preventing erectile dysfunction
US20040180857A1 (en) * 1998-08-24 2004-09-16 Senanayake Chrisantha Hugh Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US20040180952A1 (en) * 1998-12-01 2004-09-16 Sepracor Inc. Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same
US20060199860A1 (en) * 1998-12-01 2006-09-07 Jerussi Thomas P Salts of (-)-O-desmethylvenlafaxine
US20060199861A1 (en) * 1998-12-01 2006-09-07 Jerussi Thomas P Methods of using derivatives of (-)-venlafaxine
US8642662B2 (en) 1998-12-01 2014-02-04 Sunovion Pharmaceuticals Inc. Methods of using derivatives of (−)-venlafaxine
US6911479B2 (en) 1998-12-01 2005-06-28 Sepracor Inc. Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (−)-venlafaxine
US9072700B2 (en) 1998-12-01 2015-07-07 Sunovion Pharmaceuticals Inc. Methods of using derivatives of (−)-venlafaxine
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US20050096318A1 (en) * 1999-01-20 2005-05-05 Toby Broom Pharmaceutically active morpholinol
US20020052340A1 (en) * 1999-03-01 2002-05-02 Jerussi Thomas P. Bupropion metabolites and methods of their synthesis and use
US20100125070A1 (en) * 1999-03-01 2010-05-20 Fang Kevin Qun Bupropion Metabolites and Methods of Their Synthesis and Use
US20060058300A1 (en) * 1999-03-01 2006-03-16 Sepracor Inc. Intermediates of bupropion metabolites synthesis
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
EP1759701A2 (en) 1999-03-01 2007-03-07 Sepracor, Inc. Buproprion Metabolites and Methods of Their Synthesis and Use.
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6649183B2 (en) 1999-03-01 2003-11-18 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
US20040058973A1 (en) * 1999-03-01 2004-03-25 Sepracor Inc. Compositions for treating apnea and related disorders containing optically pure R(+) ondansetron
US6548082B1 (en) 1999-03-01 2003-04-15 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6548518B2 (en) 1999-03-02 2003-04-15 Sepracor, Inc. Methods of treating gastro-esophogeal reflux disease using (-) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6552045B2 (en) 1999-03-02 2003-04-22 Sepracor Inc. Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
US6410052B1 (en) 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
US8269040B2 (en) 1999-04-06 2012-09-18 Wyeth Llc Derivatives of venlafaxine and methods of preparing and using the same
US20050197392A1 (en) * 1999-04-06 2005-09-08 Sepracor Inc. O-desmethylvenlafaxine and methods of preparing and using the same
US20080132578A1 (en) * 1999-04-06 2008-06-05 Sepracor Inc. Dosage forms of O-desmethylvenlafaxine
EP2133325A1 (en) 1999-04-06 2009-12-16 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US6951873B1 (en) 1999-04-27 2005-10-04 Pfizer Inc. Methods for treating age-related behavioral disorders in companion animals
EP2030620A1 (en) 1999-05-07 2009-03-04 Wockhardt Limited (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974837B2 (en) 1999-08-11 2005-12-13 Sepracor Inc. Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6710087B2 (en) 1999-08-11 2004-03-23 Sepracor, Inc. Methods of treating or preventing neuropathic pain using sibutramine metabolites
US20030096792A1 (en) * 1999-08-11 2003-05-22 Sepracor, Inc. Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
EP1889614A2 (en) 1999-09-03 2008-02-20 APBI Holdings, LLC Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
US20050215617A1 (en) * 1999-09-03 2005-09-29 Apbi Holdings, Llc Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
US20050124663A1 (en) * 1999-09-17 2005-06-09 Gatlin Marjorie R. Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US20100076084A1 (en) * 1999-09-17 2010-03-25 Marjorie Regan Gatlin Method of Treating Metabolic Disorders, Especially Diabetes, or a Disease or Condition Associated with Diabetes
EP2011507A2 (en) 1999-09-17 2009-01-07 Novartis AG Pharmaceutical composition of nateglinide and another antidiabetic agent
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US20070275928A1 (en) * 1999-09-17 2007-11-29 Gatlin Marjorie R Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US20030162816A1 (en) * 1999-09-17 2003-08-28 Gatlin Marjorie Regan Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
US6265414B1 (en) 1999-10-22 2001-07-24 Schering Corporation Treating sleep disorders using desloratadine
US7276364B1 (en) 1999-11-18 2007-10-02 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
US20080096952A1 (en) * 1999-12-15 2008-04-24 Celgene Corporation Methods for the treatment of atherosclerosis, using substituted phenethylsulfones
EP2016942A1 (en) 1999-12-15 2009-01-21 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US8187630B2 (en) 1999-12-20 2012-05-29 Schering-Plough Corporation Extended release oral dosage composition
US6979463B2 (en) 1999-12-20 2005-12-27 Schering Corporation Stable extended release oral dosage composition
US20060159761A1 (en) * 1999-12-20 2006-07-20 Schering Corporation Stable extended release oral dosage composition
US6709676B2 (en) 1999-12-20 2004-03-23 Schering Corporation Extended release oral dosage composition
US7618649B2 (en) 1999-12-20 2009-11-17 Schering Corporation Extended release oral dosage composition
US7820199B2 (en) 1999-12-20 2010-10-26 Schering Corporation Stable extended release oral dosage composition
US7902208B2 (en) 2000-02-03 2011-03-08 Schering Corporation Treating allergic and inflammatory conditions
US20030119168A1 (en) * 2000-02-03 2003-06-26 Corvas International, Inc. Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US7888092B2 (en) 2000-02-03 2011-02-15 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US20110105731A1 (en) * 2000-02-03 2011-05-05 Madison Edwin L Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6432446B2 (en) 2000-02-03 2002-08-13 Bridge Pharma, Inc. Non-arrhythmogenic metabolite of oxybutynin
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
EP1602369A2 (en) 2000-02-22 2005-12-07 Sepracor, Inc. Bupropion Metabolites and Methods of their Synthesis and Use
US20090156641A1 (en) * 2000-03-31 2009-06-18 Celgene Corporation Inhibition of cyclooxygenase-2 activity
US20060199819A1 (en) * 2000-03-31 2006-09-07 Celgene Corporation Inhibition of cyclooxygenase-2 activity
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US20100280249A1 (en) * 2000-11-30 2010-11-04 The Children's Medical Center Corporation Synthesis of 4-amino-thalidomide enantiomers
US20080306113A1 (en) * 2000-11-30 2008-12-11 Anthony Treston Methods for treating macular degeneration using 4-(amino)-2-(2,6-dioxo(3-piperidyle))-isoindoline-1,3-dione
US7812169B2 (en) 2000-11-30 2010-10-12 The Children's Medical Center Corporation Method of synthesis of 4-amino-thalidomide enantiomers
US8153806B2 (en) 2000-11-30 2012-04-10 The Children's Medical Center Corporation Synthesis of 4-amino-thalidomide enantiomers
US20040147558A1 (en) * 2000-11-30 2004-07-29 Anthony Treston Synthesis of 3-amino-thalidomide and its enantiomers
US20030167524A1 (en) * 2000-12-19 2003-09-04 Rooijen Gijs Van Methods for the production of multimeric protein complexes, and related compositions
US20070037884A1 (en) * 2001-02-12 2007-02-15 Wyeth Novel succinate salt of O-desmethyl-venlafaxine
US7291347B2 (en) 2001-02-12 2007-11-06 Wyeth Succinate salt of O-desmethyl-venlafaxine
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US6894189B2 (en) 2001-04-13 2005-05-17 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20040087660A1 (en) * 2001-04-13 2004-05-06 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20050065164A1 (en) * 2001-04-25 2005-03-24 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US20030096812A1 (en) * 2001-04-25 2003-05-22 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-Quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US7393957B2 (en) 2001-04-25 2008-07-01 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US7626032B2 (en) 2001-04-25 2009-12-01 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US20030096019A1 (en) * 2001-07-02 2003-05-22 Currie Mark G. Methods of using norfluoxetine
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
US20040247696A1 (en) * 2001-07-05 2004-12-09 Antelman Marvin S. Methods of using electron active compounds for managing conditions afflicting mammals
WO2003022259A1 (en) 2001-09-13 2003-03-20 Sepracor Inc. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
US20030107149A1 (en) * 2001-10-12 2003-06-12 International Fluidics. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8685437B2 (en) 2001-10-12 2014-04-01 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20080260805A1 (en) * 2001-10-12 2008-10-23 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20040258896A1 (en) * 2001-10-12 2004-12-23 Monosolrx Llc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7910641B2 (en) 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8652378B1 (en) 2001-10-12 2014-02-18 Monosol Rx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8906277B2 (en) 2001-10-12 2014-12-09 Monosol Rx, Llc Process for manufacturing a resulting pharmaceutical film
US20070281003A1 (en) * 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20100021526A1 (en) * 2001-10-12 2010-01-28 Monosol Rx, Llc Ph modulated films for delivery of actives
US20070149731A1 (en) * 2001-10-12 2007-06-28 Monosolrx, Llc. PH modulated films for delivery of actives
US20070154527A1 (en) * 2001-10-12 2007-07-05 Monosoirx, Llc Topical film compositions for delivery of actives
US7824588B2 (en) 2001-10-12 2010-11-02 Monosol Rx, Llc Method of making self-supporting therapeutic active-containing film
US9931305B2 (en) 2001-10-12 2018-04-03 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US9855221B2 (en) 2001-10-12 2018-01-02 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070208087A1 (en) * 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US8754133B2 (en) 2001-11-02 2014-06-17 Proteotech, Inc. Compounds, compositions and methods for the treatment of inflammatory diseases
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
EP2002827A2 (en) 2001-12-05 2008-12-17 The Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20070027109A1 (en) * 2002-01-10 2007-02-01 Monash University Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20060084631A1 (en) * 2002-01-10 2006-04-20 Monash University Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
EP2033951A2 (en) 2002-02-01 2009-03-11 Euro-Celtique S.A. 2-Piperazine-pyridines useful for treating pain
US8362062B2 (en) 2002-02-15 2013-01-29 Mcneil-Ppc, Inc. Pharmaceutical compositions with improved dissolution
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20050070551A1 (en) * 2002-02-15 2005-03-31 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20060134198A1 (en) * 2002-02-15 2006-06-22 Mark Tawa Pharmaceutical compositions with improved dissolution
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
EP2074995A1 (en) 2002-03-20 2009-07-01 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP2223688A1 (en) 2002-03-20 2010-09-01 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
EP2223687A1 (en) 2002-03-20 2010-09-01 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
EP2962690A1 (en) 2002-03-20 2016-01-06 Celgene Corporation (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP2420490A1 (en) 2002-03-20 2012-02-22 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20080044454A1 (en) * 2002-04-11 2008-02-21 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20080260809A1 (en) * 2002-04-11 2008-10-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20040024031A1 (en) * 2002-05-03 2004-02-05 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US20080206193A1 (en) * 2002-05-17 2008-08-28 Zeldis Jerome B Method for treatment and management of thyroid cancer using immunomodulatory compounds
US9056103B2 (en) 2002-05-17 2015-06-16 Celgene Corporation Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US8735428B2 (en) 2002-05-17 2014-05-27 Celgene Corporation Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
US8722647B2 (en) 2002-05-17 2014-05-13 Celgene Corporation Methods for treating amyloidosis using 4-(amino)-2-(2,6-Dioxo(3-piperidyl))- isoindoline-1,3-dione
US8722705B2 (en) 2002-05-17 2014-05-13 Celgene Corporation Methods for treating diffuse large B-cell lymphoma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
EP2258363A1 (en) 2002-05-17 2010-12-08 Celgene Corporation Compositions for treatment of cancers
EP2561874A2 (en) 2002-05-17 2013-02-27 Celgene Corporation Pharmaceutical compositions for treating cancer
US8623384B2 (en) 2002-05-17 2014-01-07 Celgene Corporation Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of acute myelogenous leukemia
US9393238B2 (en) 2002-05-17 2016-07-19 Celgene Corporation Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
US7468363B2 (en) 2002-05-17 2008-12-23 Celgene Corporation Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20080317708A1 (en) * 2002-05-17 2008-12-25 Celgene Corporation Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3dione
US20080317709A1 (en) * 2002-05-17 2008-12-25 Celgene Corporation Methods for treating head or neck cancer using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
US20060030594A1 (en) * 2002-05-17 2006-02-09 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US8410136B2 (en) 2002-05-17 2013-04-02 Celgene Corporation Methods for treatment of hepatocellular carcinoma using 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
US20080219949A1 (en) * 2002-05-17 2008-09-11 Celgene Corporation Methods for treating brain cancer using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione
US8759375B2 (en) 2002-05-17 2014-06-24 Celgene Corporation Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with proteasome inhibitor
US8673939B2 (en) 2002-05-17 2014-03-18 Celgene Corporation Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
US20100063094A1 (en) * 2002-05-17 2010-03-11 Celgene Corporation Methods for treatment of colorectal cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US9101622B2 (en) 2002-05-17 2015-08-11 Celgene Corporation Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone
US20090010877A1 (en) * 2002-05-17 2009-01-08 Celgene Corporation Methods for treatment prostate cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20060199843A1 (en) * 2002-05-17 2006-09-07 Zeldis Jerome B Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
EP2915533A1 (en) 2002-05-17 2015-09-09 Celgene Corporation Pharmaceutical compositions for treating cancer
US20050234017A1 (en) * 2002-05-17 2005-10-20 Sol Barer Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP2272512A1 (en) 2002-05-17 2011-01-12 Celgene Corporation Pharmaceutical compositions for treating cancer
US9498472B2 (en) 2002-05-17 2016-11-22 Celgene Corporation Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20100196369A1 (en) * 2002-05-17 2010-08-05 Celgene Corporation Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
US8492406B2 (en) 2002-05-17 2013-07-23 Celgene Corporation Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
US8207200B2 (en) 2002-05-17 2012-06-26 Celgene Corporation Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroindol-2-yl)-piperidine-2,6-dione follow by autologous stem cell transplantation
US9155730B2 (en) 2002-05-17 2015-10-13 Calgene Corporation Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
US20080219948A1 (en) * 2002-05-17 2008-09-11 Celgene Corporation Methods for treatment of behcet's disease using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US9283215B2 (en) 2002-05-17 2016-03-15 Celgene Corporation Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with antibodies
US8198262B2 (en) 2002-05-17 2012-06-12 Celgene Corporation Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
US8198306B2 (en) 2002-05-17 2012-06-12 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a proteasome inhibitor
US8530498B1 (en) 2002-05-17 2013-09-10 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione
US9101621B2 (en) 2002-05-17 2015-08-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US8648095B2 (en) 2002-05-17 2014-02-11 Celgene Corporation Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor
US8188118B2 (en) 2002-05-17 2012-05-29 Celgene Corporation Method for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with antibodies
US20080145368A1 (en) * 2002-05-17 2008-06-19 Celgene Corporation Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
EP2105135A2 (en) 2002-05-17 2009-09-30 Celgene Corporation Pharmaceutical compositions for treating cancer
EP2105136A2 (en) 2002-05-17 2009-09-30 Celgene Corporation Pharmaceutical compositions for treating cancer
US8440194B2 (en) 2002-05-17 2013-05-14 Celgene Corporation Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US9050324B2 (en) 2002-05-17 2015-06-09 Celgene Corporation Methods for treating amyloidosis with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
EP2087891A2 (en) 2002-05-17 2009-08-12 Celgene Corporation Pharmaceutical compositions for treating lymphoma
US9662321B2 (en) 2002-05-17 2017-05-30 Celgene Corporation Methods for treating newly diagnosed multiple myeloma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents
US8263637B2 (en) 2002-05-17 2012-09-11 Celgene Corporation Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US8632787B2 (en) 2002-05-17 2014-01-21 Celgene Corporation Methods using immunomodulatory compounds for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2316455A1 (en) 2002-05-17 2011-05-04 Celgene Corporation Pharmaceutical compositions for treating cancer
US20090155265A1 (en) * 2002-05-17 2009-06-18 Celgene Corporation Method for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with antibodies
US20090123416A1 (en) * 2002-05-17 2009-05-14 Zeldis Jerome B Methods for the treatment of bladder cancer using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
EP2272513A1 (en) 2002-05-17 2011-01-12 Celgene Corporation Pharmaceutical compositions for treating cancer
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7514583B2 (en) 2002-05-31 2009-04-07 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
US8163957B2 (en) 2002-05-31 2012-04-24 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
EP2527315A1 (en) 2002-05-31 2012-11-28 Proteotech Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
US20040019211A1 (en) * 2002-05-31 2004-01-29 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US20050234084A1 (en) * 2002-05-31 2005-10-20 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
US20040127555A1 (en) * 2002-05-31 2004-07-01 Snow Alan D. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and parkinson's disease
US7414062B2 (en) 2002-05-31 2008-08-19 Purdue Pharma L.P. Triazaspiro compounds useful for treating or preventing pain
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7659282B2 (en) 2002-07-17 2010-02-09 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20050203125A1 (en) * 2002-07-17 2005-09-15 Gerald Yakatan Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US8227484B2 (en) 2002-07-17 2012-07-24 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20090082384A1 (en) * 2002-07-17 2009-03-26 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EP2322179A1 (en) 2002-07-17 2011-05-18 Avanir Pharmaceuticals, Inc. Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders
EP3281630A1 (en) 2002-07-17 2018-02-14 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EP1980252A2 (en) 2002-07-17 2008-10-15 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20100137352A1 (en) * 2002-07-17 2010-06-03 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2004009558A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
US6825205B2 (en) 2002-09-25 2004-11-30 Euro-Celtique S.A. N-substituted hydromorphones and the use thereof
US7772206B2 (en) 2002-09-27 2010-08-10 Genzyme Corporation Methods and compositions for the treatment of autoimmune disorders using clofarabine
US20090297478A1 (en) * 2002-09-27 2009-12-03 Wood Christopher B Methods and Compositions for the Treatment of Lupus Using Clofarabine
US20090155211A1 (en) * 2002-09-27 2009-06-18 Wood Christopher B Methods and Compositions for the Treatment of Autoimmune Disorders Using Clofarabine
US20040260076A1 (en) * 2002-10-11 2004-12-23 Castillo Gerardo M. Isolation, purification and synthesis of procyanidin B2 and uses thereof
US7863297B2 (en) 2002-10-15 2011-01-04 Celgene Corporation Methods of using 4-(amino)-2-(2,6-dioxo(3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromes
US7842691B2 (en) 2002-10-15 2010-11-30 Celgene Corporation Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US9056120B2 (en) 2002-10-15 2015-06-16 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US9925207B2 (en) 2002-10-15 2018-03-27 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US20040220144A1 (en) * 2002-10-15 2004-11-04 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US20110172273A1 (en) * 2002-10-15 2011-07-14 Zeldis Jerome B Methods of treating myelodysplastic syndromes using lenalidomide
US20060147416A1 (en) * 2002-10-15 2006-07-06 Celgene Corporation Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes
US20100278779A1 (en) * 2002-10-15 2010-11-04 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7393863B2 (en) 2002-10-15 2008-07-01 Celgene Corporation Methods of using N-{[2-(2,6-dioxo(3-piperidyl)-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl-carboxamide for the treatment and management of myelodysplastic syndromes
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US20070196330A1 (en) * 2002-10-15 2007-08-23 Celgene Corporation Methods of using N-{[2-(2,6-dioxo(3-piperidyl)-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl-carboxamide for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
EP2036553A1 (en) 2002-10-24 2009-03-18 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US20110038832A1 (en) * 2002-10-31 2011-02-17 Celgene Corporation Method for treatment of macular degeneration using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7354948B2 (en) 2002-11-06 2008-04-08 Celgene Corporation Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP2210606A2 (en) 2002-11-06 2010-07-28 Celgene Corporation Methods Of Using And Compositions Comprising Immunomodulatory Compounds For The Treatment And Management Of Myeloproliferative Diseases
US20060165649A1 (en) * 2002-11-06 2006-07-27 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US8026254B2 (en) 2002-11-18 2011-09-27 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20100069437A1 (en) * 2002-11-18 2010-03-18 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20060247296A1 (en) * 2002-11-18 2006-11-02 Muller George W Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20040167199A1 (en) * 2002-11-18 2004-08-26 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
EP2298874A1 (en) 2002-12-16 2011-03-23 Halozyme, Inc. Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
US8815558B2 (en) 2002-12-16 2014-08-26 Halozyme, Inc. Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
EP2218779A1 (en) 2002-12-16 2010-08-18 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US20100015698A1 (en) * 2002-12-16 2010-01-21 Halozyme, Inc. Human Chondroitinase Glycoprotein (CHASEGP), Process for Preparing the Same, and Pharmaceutical Compositions Comprising Thereof
US20100004254A1 (en) * 2002-12-24 2010-01-07 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US8008300B2 (en) 2002-12-24 2011-08-30 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8604037B2 (en) 2002-12-24 2013-12-10 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US8536177B2 (en) 2002-12-24 2013-09-17 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US9434721B2 (en) 2002-12-24 2016-09-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20040186111A1 (en) * 2002-12-24 2004-09-23 Qun Sun Therapeutic agents useful for treating pain
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP2339328A2 (en) 2002-12-30 2011-06-29 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8492423B2 (en) 2002-12-30 2013-07-23 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2004081001A1 (en) 2003-02-13 2004-09-23 Banyu Pharmaceutical Co., Ltd. Novel 2-pyridinecarboxamide derivatives
WO2004078161A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8105586B2 (en) 2003-03-05 2012-01-31 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP3009517A1 (en) 2003-03-05 2016-04-20 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8431124B2 (en) 2003-03-05 2013-04-30 Halozyme, Inc. Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
EP2177620A1 (en) 2003-03-05 2010-04-21 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050260186A1 (en) * 2003-03-05 2005-11-24 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8765685B2 (en) 2003-03-05 2014-07-01 Halozyme, Inc. Methods for treating edema by administering a Soluble Hyaluronidase Glycoprotein (sHASEGP)
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US8202517B2 (en) 2003-03-05 2012-06-19 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2163643A1 (en) 2003-03-05 2010-03-17 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8450470B2 (en) 2003-03-05 2013-05-28 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20110152359A1 (en) * 2003-03-05 2011-06-23 Bookbinder Louis H Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising threreof
EP2405015A2 (en) 2003-03-05 2012-01-11 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8772246B2 (en) 2003-03-05 2014-07-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US9562223B2 (en) 2003-03-05 2017-02-07 Halozyme, Inc. Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP)
US8431380B2 (en) 2003-03-05 2013-04-30 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US9677062B2 (en) 2003-03-05 2017-06-13 Halozyme, Inc. Hyaluronidase and factor VIII compositions
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20040268425A1 (en) * 2003-03-05 2004-12-30 Deliatroph Pharmaceuticals, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20110008309A1 (en) * 2003-03-05 2011-01-13 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US9677061B2 (en) 2003-03-05 2017-06-13 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2311973A1 (en) 2003-03-05 2011-04-20 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060287392A1 (en) * 2003-04-11 2006-12-21 Transform Pharmaceuticals, Inc. Gabapentin compositions
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
EP3178816A1 (en) 2003-04-11 2017-06-14 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
EP2910551A1 (en) 2003-04-11 2015-08-26 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
EP2460522A2 (en) 2003-05-15 2012-06-06 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
US20080132541A1 (en) * 2003-05-15 2008-06-05 Celgene Corporation Methods for Treating Cancers Using Polymorphic Forms of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
US20040248987A1 (en) * 2003-05-23 2004-12-09 Aberg A.K. Gunnar Smooth muscle spasmolytic agents
US7141696B2 (en) 2003-05-23 2006-11-28 Bridge Pharma, Inc. Smooth muscle spasmolytic agents
US7186863B2 (en) 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
US20050014829A1 (en) * 2003-05-23 2005-01-20 Julius Remenar Sertraline compositions
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20050008581A1 (en) * 2003-06-06 2005-01-13 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US7683063B2 (en) 2003-06-12 2010-03-23 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20110152324A1 (en) * 2003-06-12 2011-06-23 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8680118B2 (en) 2003-06-12 2014-03-25 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20070027159A1 (en) * 2003-06-12 2007-02-01 Kyle Donald J Therapeutic agents useful for treating pain
US8227467B2 (en) 2003-06-12 2012-07-24 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20100256111A1 (en) * 2003-07-03 2010-10-07 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8058292B2 (en) 2003-07-03 2011-11-15 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20060235055A1 (en) * 2003-07-03 2006-10-19 Kyle Donald J Therapeutic agents useful for treating pain
US7767699B2 (en) 2003-07-03 2010-08-03 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20050009782A1 (en) * 2003-07-09 2005-01-13 Comper Wayne D. Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
US20050148633A1 (en) * 2003-07-23 2005-07-07 Yu Xie Method for modulating calcium ion-release-activated calcium ion channels
EP2319516A1 (en) 2003-07-23 2011-05-11 Synta Pharmaceuticals Corp. Compounds for treating inflammatory and autoimmune disorders
WO2005009539A2 (en) 2003-07-23 2005-02-03 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses
US20060128717A1 (en) * 2003-07-24 2006-06-15 Qun Sun Therapeutic agents useful for treating pain
US9301953B2 (en) 2003-07-24 2016-04-05 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8178560B2 (en) 2003-07-24 2012-05-15 Purdue Pharma L.P. Therapeutic agents useful for treating pain
EP2067776A1 (en) 2003-07-24 2009-06-10 Euro-Celtique S.A. Piperidine compounds and pharmaceutical compositions containing them
EP1867644A1 (en) 2003-07-24 2007-12-19 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
US7776861B2 (en) 2003-07-24 2010-08-17 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8349842B2 (en) 2003-07-24 2013-01-08 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20050020692A1 (en) * 2003-07-24 2005-01-27 Ciofalo Vincent B. Treatment of heaves
US8637548B2 (en) 2003-07-24 2014-01-28 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20110071192A1 (en) * 2003-07-24 2011-03-24 Purdue Pharma L.P. Therapeutic Agents Useful for Treating Pain
US20060199824A1 (en) * 2003-07-24 2006-09-07 Qun Sun Therapeutic agents useful for treating pain
US7572812B2 (en) 2003-07-24 2009-08-11 Purdue Pharma, L.P., Usa Therapeutic agents useful for treating pain
US20100331369A1 (en) * 2003-07-24 2010-12-30 Purdue Pharma L.P. Therapeutic Agents Useful for Treating Pain
US20100210686A1 (en) * 2003-07-24 2010-08-19 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20060258669A1 (en) * 2003-08-01 2006-11-16 Kyle Donald J Therapeutic agents useful for treating pain
US7696208B2 (en) 2003-08-01 2010-04-13 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8030310B2 (en) 2003-08-01 2011-10-04 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US20090062343A1 (en) * 2003-09-04 2009-03-05 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US9365538B2 (en) 2003-09-04 2016-06-14 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8143286B2 (en) 2003-09-04 2012-03-27 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione)
US7465800B2 (en) 2003-09-04 2008-12-16 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US9353080B2 (en) 2003-09-04 2016-05-31 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US9371309B2 (en) 2003-09-04 2016-06-21 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7977357B2 (en) 2003-09-04 2011-07-12 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindo1-2-yl)-piperidine-2,6-dione
US20090149499A1 (en) * 2003-09-04 2009-06-11 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione)
US20050054666A1 (en) * 2003-09-04 2005-03-10 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
US8193219B2 (en) 2003-09-04 2012-06-05 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8431598B2 (en) 2003-09-04 2013-04-30 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7164023B2 (en) 2003-09-04 2007-01-16 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
US20070167627A1 (en) * 2003-09-04 2007-07-19 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
US8822499B2 (en) 2003-09-04 2014-09-02 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8058443B2 (en) 2003-09-04 2011-11-15 Celgene Corporation Processes for preparing polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-YL))-piperidine-2,6-dione
US20110015228A1 (en) * 2003-09-04 2011-01-20 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7855217B2 (en) 2003-09-04 2010-12-21 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20090176832A1 (en) * 2003-09-04 2009-07-09 Jaworsky Markian S Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20060194840A1 (en) * 2003-09-19 2006-08-31 David Gozal Method for treating snoring and sleep apnea with leukotriene antagonists
US20110166114A1 (en) * 2003-09-19 2011-07-07 University Of Louisville Research Foundation Method for treating snoring and sleep apnea with leukotriene antagonists
US7799807B2 (en) 2003-09-22 2010-09-21 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7964606B2 (en) 2003-09-22 2011-06-21 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20100317670A1 (en) * 2003-09-22 2010-12-16 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20110009418A1 (en) * 2003-09-22 2011-01-13 Purdue Pharma L.P. Therapeutic agents useful for treating pain
EP2017276A1 (en) 2003-09-22 2009-01-21 Euro-Celtique S.A. Phenyl-carboxamide compounds useful for treating pain
US20060241117A1 (en) * 2003-09-22 2006-10-26 Qun Sun Therapeutic agents useful for treating pain
US7772254B2 (en) 2003-09-22 2010-08-10 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7994177B2 (en) 2003-09-22 2011-08-09 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8129388B2 (en) 2003-09-22 2012-03-06 Purde Pharma L.P. Therapeutic agents useful for treating pain
US20060235022A1 (en) * 2003-09-22 2006-10-19 Qun Sun Therapeutic agents useful for treating pain
US7612096B2 (en) 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20070244078A1 (en) * 2003-10-23 2007-10-18 Zeldis Jerome B Methods for Treatment, Modification and Management of Pain Using 1-Oxo-2-(2,6-Dioxopiperidin-3-yl)-4-Methylisoindoline
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
EP2077112A1 (en) 2003-11-06 2009-07-08 Celgene Corporation Methods and compositions using thalidomide for the treatment and management of cancers and idiopathic pulmonary fibrosis
US20070208057A1 (en) * 2003-11-06 2007-09-06 Zeldis Jerome B Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases
US20090081286A1 (en) * 2003-11-17 2009-03-26 Manesh Dixit Extended release venlafaxine formulation
US8668932B2 (en) 2003-11-17 2014-03-11 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20110165234A1 (en) * 2003-11-17 2011-07-07 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050106248A1 (en) * 2003-11-17 2005-05-19 Manesh Dixit Extended release venlafaxine formulation
US7931915B2 (en) 2003-11-17 2011-04-26 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP2065383A1 (en) 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Indazole compounds and methods of use thereof as protein kinase inhibitors
WO2005066126A1 (en) 2003-12-23 2005-07-21 Eli Lilly And Company Cb1 modulator compounds
US7728025B2 (en) 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
US20080070928A1 (en) * 2003-12-29 2008-03-20 Katsumasa Nonoshita Novel 2-Heteroaryl-Substituted Benzimidazole Derivative
US20070032500A1 (en) * 2003-12-30 2007-02-08 Qun Sun Therapeutic agents useful for treating pain
US7754723B2 (en) 2003-12-30 2010-07-13 Purdue Pharma, L.P., Usa Therapeutic agents useful for treating pain
US20050176757A1 (en) * 2004-01-07 2005-08-11 Aryx Therapeutics Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US7282509B2 (en) 2004-01-07 2007-10-16 Aryx Therapeutics Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US7176218B2 (en) 2004-01-07 2007-02-13 Aryx Therapeutics Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP2194053A1 (en) 2004-01-07 2010-06-09 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20080085921A1 (en) * 2004-01-07 2008-04-10 Aryx Therapeutics Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20060003001A1 (en) * 2004-02-11 2006-01-05 John Devane Chronotherapeutic compositions and methods of their use
EP1967189A1 (en) 2004-02-18 2008-09-10 GPC Biotech AG Methods for treating resistant or refractory tumors
US8257699B2 (en) 2004-03-05 2012-09-04 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US9211315B2 (en) 2004-03-05 2015-12-15 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US10016491B2 (en) 2004-03-05 2018-07-10 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8580252B2 (en) 2004-03-05 2013-11-12 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2005089767A1 (en) 2004-03-12 2005-09-29 Barton Aron Kamen Use of aminopterin for treating cancer and inflammatory disorders
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US9326972B2 (en) 2004-03-16 2016-05-03 Ohio University Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20100004304A1 (en) * 2004-03-16 2010-01-07 Kohn Leonard D Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
US20050209295A1 (en) * 2004-03-16 2005-09-22 Kohn Leonard D Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
EP2505200A1 (en) 2004-03-22 2012-10-03 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma
US20060004037A1 (en) * 2004-03-25 2006-01-05 Transform Pharmaceuticals, Inc. Novel tricyclic compounds and related methods of treatment
US8168672B2 (en) 2004-04-08 2012-05-01 Wyeth Thioamide derivatives as progesterone receptor modulators
US20090143345A1 (en) * 2004-04-08 2009-06-04 Wyeth Thioamide derivatives as progesterone receptor modulators
US7358246B2 (en) 2004-04-08 2008-04-15 Wyeth Thioamide derivatives as progesterone receptor modulators
US7659265B2 (en) 2004-04-08 2010-02-09 Wyeth Thioamide derivatives as progesterone receptor modulators
US20050227971A1 (en) * 2004-04-08 2005-10-13 Wyeth Thioamide derivatives as progesterone receptor modulators
US20080167299A1 (en) * 2004-04-08 2008-07-10 Wyeth Thioamide derivatives as progesterone receptor modulators
US20100197645A1 (en) * 2004-04-08 2010-08-05 Wyeth Llc Thioamide Derivatives as Progesterone Receptor Modulators
US7511071B2 (en) 2004-04-08 2009-03-31 Wyeth Thioamide derivatives as progesterone receptor modulators
US20080199422A1 (en) * 2004-04-14 2008-08-21 Celgene Corporation Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
US20050239867A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
US7514466B2 (en) 2004-04-27 2009-04-07 Wyeth Purification of progesterone receptor modulators
US8309594B2 (en) 2004-04-27 2012-11-13 Wyeth Llc Purification of progesterone receptor modulators
US20090143577A1 (en) * 2004-04-27 2009-06-04 Wyeth Purification of progesterone receptor modulators
US8609712B2 (en) 2004-04-27 2013-12-17 Wyeth Llc Purification of progesterone receptor modulators
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US20060052438A1 (en) * 2004-04-30 2006-03-09 Chi-Tang Ho Bioactive compounds and methods of uses thereof
US20090054530A1 (en) * 2004-05-07 2009-02-26 Nbty, Inc. Methods and Compositions that Enhance Bioavailability of Coenzyme-Q10
US7803366B2 (en) 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20060286102A1 (en) * 2004-05-14 2006-12-21 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US20080108630A1 (en) * 2004-05-25 2008-05-08 Metabolex Inc. Substituted triazoles as modulators of ppar and methods of their preparation
US7323480B2 (en) 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
US20060014809A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
US20100190728A1 (en) * 2004-05-28 2010-07-29 Human Biomolecular Research Institute Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents
US7671093B2 (en) 2004-05-28 2010-03-02 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
US8481501B2 (en) 2004-05-28 2013-07-09 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
US20080138282A1 (en) * 2004-06-03 2008-06-12 The Trustees Of Columbia University In The City Of New York Radiolabeled Arylsulfonyl Compounds and Uses Thereof
US20070299033A1 (en) * 2004-06-17 2007-12-27 Trans Form Pharmaceuticals, Inc. Pharmaceutical Co-Crystal Compositions and Related Methods of Use
US7803786B2 (en) 2004-06-17 2010-09-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
US20080261967A1 (en) * 2004-06-19 2008-10-23 John Cashman Modulators of Central Nervous System Neurotransmitters
US8168635B2 (en) 2004-06-19 2012-05-01 Human Biomolecular Research Institute Modulators of central nervous system neurotransmitters
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
US7928132B2 (en) 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
US7642287B2 (en) 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
US20090149533A1 (en) * 2004-08-06 2009-06-11 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20060034815A1 (en) * 2004-08-06 2006-02-16 Hector Guzman Novel statin pharmaceutical compositions and related methods of treatment
US20060058365A1 (en) * 2004-08-06 2006-03-16 Kohn Leonard D Compositions and methods for treatment of colitis
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
EP2433634A2 (en) 2004-09-17 2012-03-28 The Whitehead Institute for Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
US8440705B2 (en) 2004-09-17 2013-05-14 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
US20100311787A1 (en) * 2004-09-21 2010-12-09 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8314134B2 (en) 2004-09-21 2012-11-20 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8524756B2 (en) 2004-09-21 2013-09-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US20090170790A1 (en) * 2004-10-25 2009-07-02 Biswajit Das Ketolide derivatives as antibacterial agents
US20060106085A1 (en) * 2004-10-28 2006-05-18 Zeldis Jerome B Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
WO2006049304A1 (en) 2004-11-02 2006-05-11 Banyu Pharmaceutical Co., Ltd Aryloxy-substituted benzimidazole derivatives
US20080160099A1 (en) * 2004-11-10 2008-07-03 The Trustees Of Columbia University In The City Of New York Methods For Treating or Preventing a Vascular Disease
EP2298748A2 (en) 2004-11-18 2011-03-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
EP2295416A2 (en) 2004-11-18 2011-03-16 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
US8637087B2 (en) 2004-12-13 2014-01-28 Jb Therapeutics Inc. Treatment of interstitial cystitis using (6aR, 10aR)-Δ8-tetrahydrocannabinol-11-OIC acids
US20060128738A1 (en) * 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
US8101745B2 (en) 2004-12-16 2012-01-24 The Regents Of The University Of California Lung-targeted drugs
US8318700B2 (en) 2004-12-16 2012-11-27 The Regents Of The University Of California Lung-targeted drugs
WO2006066074A2 (en) 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
US20080221061A1 (en) * 2004-12-16 2008-09-11 The Regents Of The University Of California Lung-Targeted Drugs
EP2561872A1 (en) 2004-12-17 2013-02-27 Anadys Pharmaceuticals, Inc. 3, 5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof
EP2096107A1 (en) 2004-12-23 2009-09-02 GPC Biotech AG Derivatives of squaric acid with anti-proliferative activity
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
US20060173006A1 (en) * 2005-01-07 2006-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8202999B2 (en) 2005-01-07 2012-06-19 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8592486B2 (en) 2005-01-07 2013-11-26 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2006081391A2 (en) 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US9090570B2 (en) 2005-01-25 2015-07-28 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US9493427B2 (en) 2005-01-25 2016-11-15 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8518950B2 (en) 2005-01-25 2013-08-27 Synta Pharmaceuticals Corp. 2-amido pyrazines for inflammation and immune related uses
US20060173021A1 (en) * 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
EP3045472A1 (en) 2005-02-23 2016-07-20 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7829081B2 (en) 2005-02-23 2010-11-09 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2006091871A1 (en) 2005-02-23 2006-08-31 Halozyme Therapeutics, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20100196423A1 (en) * 2005-02-23 2010-08-05 Bookbinder Louis H Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7846431B2 (en) 2005-02-23 2010-12-07 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US9867828B2 (en) 2005-03-11 2018-01-16 Aminopterin Llc Aminopterin dosage forms
WO2006102426A2 (en) 2005-03-21 2006-09-28 Metabolex, Inc. Methods for avoiding edema in the treatment of metabolic, inflammatory, and cardiovascular disorders
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US7592335B2 (en) 2005-04-15 2009-09-22 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US20080188470A1 (en) * 2005-04-15 2008-08-07 Ranbaxy Laboratories Limited Oxazolidinone Derivatives as Antimicrobials
WO2006119365A2 (en) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
EP2399578A1 (en) 2005-05-17 2011-12-28 The Interthyr Corporation Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20090111818A1 (en) * 2005-07-06 2009-04-30 Sepracor Inc. Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
WO2007013929A1 (en) 2005-07-22 2007-02-01 Amgen Inc. Aniline sulfonamide derivatives and their uses
US20090137810A1 (en) * 2005-08-31 2009-05-28 Aryx Therapeutics, Inc. Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders
US7326787B2 (en) 2005-08-31 2008-02-05 Aryx Therapeutics, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007027527A2 (en) 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US20080076927A1 (en) * 2005-08-31 2008-03-27 Aryx Therapeutics, Inc. Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders
US20070078265A1 (en) * 2005-08-31 2007-04-05 Aryx Therapeutics Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders
WO2007028073A2 (en) 2005-08-31 2007-03-08 Aryx Therapeutics, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
US7629466B2 (en) 2005-08-31 2009-12-08 Aryx Therapeutics, Inc. Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007033112A1 (en) 2005-09-12 2007-03-22 Celgene Corporation Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US8492428B2 (en) 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US20100260778A1 (en) * 2005-09-20 2010-10-14 Yuan-Ping Pang Small-molecule botulinum toxin inhibitors
US20090118304A1 (en) * 2005-09-30 2009-05-07 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
US7799820B2 (en) 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
WO2007037534A1 (en) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
EP2526946A1 (en) 2005-10-04 2012-11-28 Celgene Corporation Methods Using 3-(4-Amino-1-Oxo-1,3-Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione For Treatment Of Certain Leukemias
US20070092585A1 (en) * 2005-10-14 2007-04-26 Skinner Michael K Cancer chemotherapy compositions comprising PI3K pathways modulators and triptolide
EP2298770A1 (en) 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
EP2289497A1 (en) 2005-11-10 2011-03-02 Circ Pharma Research and Development Limited Once-daily administration of central nervous system drugs
US20070161081A1 (en) * 2005-11-10 2007-07-12 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
US20080319020A1 (en) * 2005-11-21 2008-12-25 Purdue Pharma L.P. 4-Oxadiazolyl-Piperidine Compounds and Use Thereof
EP2298765A1 (en) 2005-11-21 2011-03-23 Purdue Pharma LP 4-Oxadiazolyl-piperidine compounds and use thereof
EP2298764A1 (en) 2005-11-21 2011-03-23 Purdue Pharma LP 4-Oxadiazolyl-piperidine compounds and use thereof
US20090306014A1 (en) * 2005-12-28 2009-12-10 Acidophil Llc C-10 carbamates of taxanes
US8138361B2 (en) 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
US20110104144A1 (en) * 2005-12-29 2011-05-05 Celgene Corporation Methods for treating cutaneous lupus using aminoisoindoline compounds
US20070190127A1 (en) * 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
EP2918283A1 (en) 2005-12-30 2015-09-16 Zensun (Shanghai) Science and Technology Limited Extended release of neuregulin for improved cardiac function
US20070190157A1 (en) * 2006-01-20 2007-08-16 Monosoirx, Llc. Film lined packaging and method of making same
US20070172515A1 (en) * 2006-01-20 2007-07-26 Monosolrx, Llc Film bandage for mucosal administration of actives
US20070254925A1 (en) * 2006-01-25 2007-11-01 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2007087442A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
WO2007087443A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
US8455658B2 (en) 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
US20100249195A1 (en) * 2006-01-31 2010-09-30 Synta Pharmaceuticals Corp Pyridylphenyl compounds for inflammation and immune-related uses
WO2007089904A2 (en) 2006-01-31 2007-08-09 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
US8710083B2 (en) 2006-01-31 2014-04-29 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
US20090111846A1 (en) * 2006-02-03 2009-04-30 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders
US7518017B2 (en) 2006-02-17 2009-04-14 Idexx Laboratories Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
US20070197823A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
US20080076812A1 (en) * 2006-03-13 2008-03-27 Jinling Chen Formulations of sitaxsentan sodium
US8063221B2 (en) 2006-03-13 2011-11-22 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as GSK-3 inhibitors
US20070254866A1 (en) * 2006-03-13 2007-11-01 Oana Cociorva Aminoquinolones as GSK-3 inhibitors
US20070232671A1 (en) * 2006-03-13 2007-10-04 Given Bruce D Methods and compositions for treatment of diastolic heart failure
EP2383271A1 (en) 2006-03-13 2011-11-02 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as GSK-3 Inhibitors
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
EP2865381A1 (en) 2006-05-18 2015-04-29 Pharmacyclics, Inc. ITK inhibitors for treating blood cell malignancies
EP1867321A3 (en) * 2006-06-07 2008-11-19 Familplan Consulting Ltd. A pharmaceutical product adapted for oral transmucosal administration comprising a pharmaceutical agent
EP1867321A2 (en) * 2006-06-07 2007-12-19 Familplan Consulting Ltd. A pharmaceutical product adapted for oral transmucosal administration comprising a pharmaceutical agent
US8772296B2 (en) 2006-06-08 2014-07-08 Amgen Inc. Benzamide derivatives and uses related thereto
US20070299080A1 (en) * 2006-06-08 2007-12-27 Amgen Inc. Benzamide derivatives and uses related thereto
US7659287B2 (en) 2006-06-08 2010-02-09 Amgen Inc. Benzamide derivatives and uses related thereto
US20070299111A1 (en) * 2006-06-08 2007-12-27 Amgen Inc. Benzamide derivatives and uses related thereto
US20100055093A1 (en) * 2006-06-12 2010-03-04 Receptor Biologix Inc. Pan-cell surface receptor-specific therapeutics
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
WO2007150002A2 (en) 2006-06-22 2007-12-27 Anadys Pharmaceuticals, Inc. PRODRUGS OF 5-AMINO-3-(3'-DEOXY-β-D-RIBOFURANOSYL)-THIAZOLO[4,5-d] PYRIMIDIN-2,7-DIONE
WO2007150001A1 (en) 2006-06-22 2007-12-27 Anadys Pharmaceuticals, Inc. Pyrro[1,2-b]pyridazinone compounds
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8211428B2 (en) 2006-07-05 2012-07-03 Torrey Pines Institute For Molecular Studies Protease screening methods and proteases identified thereby
US20090123452A1 (en) * 2006-07-05 2009-05-14 Madison Edwin L Protease screening methods and proteases identified thereby
EP2402438A2 (en) 2006-07-05 2012-01-04 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
US9290757B2 (en) 2006-07-05 2016-03-22 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
EP2402437A2 (en) 2006-07-05 2012-01-04 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
US8663633B2 (en) 2006-07-05 2014-03-04 Torrey Pines Institute For Molecular Studies Protease screening methods and proteases identified thereby
EP3034607A1 (en) 2006-07-05 2016-06-22 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
EP2851064A2 (en) 2006-07-11 2015-03-25 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
WO2008011406A2 (en) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
US20100068206A1 (en) * 2006-08-03 2010-03-18 Celgene Corporation Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
US20080038263A1 (en) * 2006-08-03 2008-02-14 Zeldis Jerome B Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
US8741929B2 (en) 2006-08-03 2014-06-03 Celgene Corporation Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
WO2008019065A1 (en) 2006-08-03 2008-02-14 Celgene Corporation Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
US20100144886A1 (en) * 2006-08-04 2010-06-10 Agi Therapeutics Research Limited Method for treating pulmonary arterial hypertension
US20080045603A1 (en) * 2006-08-04 2008-02-21 John Devane Methods for treating at least one condition having MT1 receptor, 5HT2B receptor, and L-type calcium channel activity
WO2008021369A2 (en) 2006-08-14 2008-02-21 Chembridge Research Laboratories, Inc. Tricyclic compounds and its use as tyrosine kinase modulators
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
WO2008027542A2 (en) 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
US7972618B2 (en) 2006-09-20 2011-07-05 Monosol Rx, Llc Edible water-soluble film containing a foam reducing flavoring agent
US20080075825A1 (en) * 2006-09-20 2008-03-27 Fuisz Richard C Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent
WO2008039489A2 (en) 2006-09-26 2008-04-03 Celgene Corporation 5-substituted quinazolinone derivatives as antitumor agents
WO2008039520A2 (en) 2006-09-26 2008-04-03 Synta Pharmaceuticals Corp. Fused ring compounds for inflammation and immune-related uses
EP3239144A1 (en) 2006-09-26 2017-11-01 Celgene Corporation 5-substituted quinazolinone derivatives as anti-cancer agents
EP2420498A1 (en) 2006-09-26 2012-02-22 Celgene Corporation 5-substituted quinazolinone derivatives as anti-cancer agents
EP2420497A1 (en) 2006-09-26 2012-02-22 Celgene Corporation 5-substituted quinazolinone derivatives as anti-cancer agents
EP2428513A1 (en) 2006-09-26 2012-03-14 Celgene Corporation 5-substituted quinazolinone derivatives as anti-cancer agents
US20080081071A1 (en) * 2006-09-29 2008-04-03 Pradeep Sanghvi Film Embedded Packaging and Method of Making Same
WO2008044777A1 (en) 2006-10-06 2008-04-17 Banyu Pharmaceutical Co., Ltd. 2-pyridinecarboxamide derivative having gk-activating activity
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
US20100143469A1 (en) * 2006-10-09 2010-06-10 Paul Bosse Pharmaceutical compositions
US9399022B2 (en) 2006-10-09 2016-07-26 Locl Pharma, Inc. Pharmaceutical compositions
US9393207B2 (en) 2006-10-09 2016-07-19 Locl Pharma, Inc. Pharmaceutical compositions
US9402813B2 (en) 2006-10-09 2016-08-02 Locl Pharma, Inc. Pharmaceutical compositions
US9427407B2 (en) 2006-10-09 2016-08-30 Locl Pharma, Inc. Pharmaceutical compositions
US8518958B2 (en) 2006-10-16 2013-08-27 Forma Therapeutics, Inc. Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors
US20110201594A1 (en) * 2006-10-16 2011-08-18 Krisna Murthi Pyrido [2,3-d] pyrimidines and their use as kinase inhibitors
EP2617423A1 (en) 2006-10-19 2013-07-24 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
WO2008049116A2 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
WO2008063504A2 (en) 2006-11-13 2008-05-29 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
WO2008066131A1 (en) 2006-12-01 2008-06-05 Banyu Pharmaceutical Co., Ltd. Novel phenyl-isoxazol-3-ol derivative
US20080188528A1 (en) * 2006-12-22 2008-08-07 Biediger Ronald J Modulators of C3a receptor and methods of use thereof
US7932421B2 (en) 2006-12-26 2011-04-26 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
US20080221175A1 (en) * 2006-12-26 2008-09-11 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
US20100130511A1 (en) * 2006-12-28 2010-05-27 Metabolex, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8975258B2 (en) 2006-12-28 2015-03-10 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8288384B2 (en) 2006-12-28 2012-10-16 Metabolex, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US9737537B2 (en) 2006-12-28 2017-08-22 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8921350B2 (en) 2006-12-28 2014-12-30 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US9925189B2 (en) 2006-12-28 2018-03-27 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
EP2280008A2 (en) 2007-01-16 2011-02-02 Purdue Pharma L.P. Heterocyclic-substituted piperidines as ORL-1 ligands
US8110602B2 (en) 2007-01-16 2012-02-07 Purdue Pharma L.P. Compounds comprising heterocyclic-substituted piperidine for treating pain
US8637502B2 (en) 2007-01-16 2014-01-28 Purde Pharma L.P. 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain
US20100022519A1 (en) * 2007-01-16 2010-01-28 Brown Kevin C Heterocyclic-substituted piperidine compounds and the uses thereof
WO2008094476A1 (en) 2007-01-31 2008-08-07 Merck & Co., Inc. Substituted pyrano [2, 3 - b] pyridine derivatives as cannabinoid -1 receptor modulators
US8710236B2 (en) 2007-02-09 2014-04-29 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US9701626B2 (en) 2007-02-09 2017-07-11 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US9169201B2 (en) 2007-02-09 2015-10-27 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
EP2786985A2 (en) 2007-02-09 2014-10-08 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
EP2500337A2 (en) 2007-02-21 2012-09-19 Sepracor Inc. Solid form comprising (-) o-desmethylvenlafaxine and uses thereof
US20080207605A1 (en) * 2007-02-28 2008-08-28 Spada Alfred P Combination therapy for the treatment of liver diseases
US20080207569A1 (en) * 2007-02-28 2008-08-28 Spada Alfred P Methods for the treatment of liver diseases
WO2008106166A2 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
US20110212056A1 (en) * 2007-02-28 2011-09-01 Conatus Pharmaceuticals, Inc. Combination therapy for the treatment of liver diseases
US20080249148A1 (en) * 2007-03-09 2008-10-09 Wyeth Synthesis and characterization of polymorph form III 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
EP3130580A1 (en) 2007-03-15 2017-02-15 Auspex Pharmaceuticals, Inc. Preparation of deuterated venlafaxines
EP2514740A1 (en) 2007-03-15 2012-10-24 Auspex Pharmaceuticals, Inc. Deuterated O-desmethylvenlafaxines with serotoninergic and/or norepinephrinergic activity
EP3103790A1 (en) 2007-03-15 2016-12-14 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
EP3269706A1 (en) 2007-03-15 2018-01-17 Auspex Pharmaceuticals, Inc. Deuterated o-desmethylvenlafaxine with serotoninergic and/or norepinephrinergic activity
WO2008122967A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited An oral pharmaceutical composition
EP2409691A1 (en) 2007-04-04 2012-01-25 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
WO2008122965A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
EP2380564A2 (en) 2007-04-04 2011-10-26 Sigmoid Pharma Limited An oral pharmaceutical composition
EP2586428A1 (en) 2007-04-26 2013-05-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
US8476277B2 (en) 2007-04-27 2013-07-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9878991B2 (en) 2007-04-27 2018-01-30 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9365563B2 (en) 2007-04-27 2016-06-14 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US8889690B2 (en) 2007-04-27 2014-11-18 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US20090176796A1 (en) * 2007-04-27 2009-07-09 Purdue Pharma L. P. Trpv1 antagonists including amide substituent and uses thereof
US20090170868A1 (en) * 2007-04-27 2009-07-02 Purdue Pharma L. P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US8389549B2 (en) 2007-04-27 2013-03-05 Purdue Pharma L.P. Substituted pyridines useful for treating pain
EP2604598A1 (en) 2007-04-27 2013-06-19 Purdue Pharma L.P. TRPV1 antagonists and uses thereof
US20100130552A1 (en) * 2007-04-27 2010-05-27 Laykea Tafesse Therapeutic Agents Useful for Treating Pain
US20090170867A1 (en) * 2007-04-27 2009-07-02 Shionogi & Co., Ltd. Trpv1 antagonists including sulfonamide substituent and uses thereof
EP2479173A1 (en) 2007-04-27 2012-07-25 Purdue Pharma LP Therapeutic agents useful for treating pain
EP2604599A1 (en) 2007-04-27 2013-06-19 Purdue Pharma LP TRPV1 antagonists and uses thereof
US8575199B2 (en) 2007-04-27 2013-11-05 Purdue Pharma L.P. Formula (IA″) compounds comprising (piperidin-4-yl)pyridine or (1,2,3,6-tetrahydropyridin-4-4yl) as TRPV1 antagonists
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
US20100160350A1 (en) * 2007-05-29 2010-06-24 Kluge Arthur F Pyrazolopyrimidinone kinase inhibitor
US8304418B2 (en) 2007-05-29 2012-11-06 Agennix Ag Pyrazolopyrimidinone kinase inhibitor
EP2617704A1 (en) 2007-05-31 2013-07-24 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP3296289A2 (en) 2007-05-31 2018-03-21 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP2572712A2 (en) 2007-06-01 2013-03-27 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
EP2581081A2 (en) 2007-06-01 2013-04-17 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US8415294B2 (en) 2007-06-05 2013-04-09 Arizona Board Of Regents Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
US20100197570A1 (en) * 2007-06-05 2010-08-05 Arizona Board of Regents ,a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz Cyclodepsipeptides with Antineoplastic Activity and Methods of Using to Inhibit Cancer and Microbial Growth
EP3150589A1 (en) 2007-06-08 2017-04-05 MannKind Corporation Ire-1a inhibitors
EP2520561A1 (en) 2007-06-08 2012-11-07 MannKind Corporation IRE-1A Inhibitors
EP2532643A1 (en) 2007-06-08 2012-12-12 MannKind Corporation IRE-1A Inhibitors
US20090042987A1 (en) * 2007-07-06 2009-02-12 Michael Lionel Selley Treatment of neuropathic pain
US20090017024A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders
US8247423B2 (en) 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
US20100197772A1 (en) * 2007-07-18 2010-08-05 Andrea Califano Tissue-Specific MicroRNAs and Compositions and Uses Thereof
US8586726B2 (en) 2007-07-18 2013-11-19 The Trustees Of Columbia University In The City Of New York Tissue-specific MicroRNAs and compositions and uses thereof
US20090137590A1 (en) * 2007-07-19 2009-05-28 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8846675B2 (en) 2007-07-19 2014-09-30 Cymabay Therapeutics, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8183381B2 (en) 2007-07-19 2012-05-22 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009017818A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Heterocycle-aryl compounds for inflammation and immune-related uses
WO2009017831A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
US20110064735A1 (en) * 2007-08-07 2011-03-17 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
US8940927B2 (en) 2007-08-13 2015-01-27 Metabasis Therapeutics, Inc. Activators of glucokinase
US9522926B2 (en) 2007-08-13 2016-12-20 Metabasis Therapeutics, Inc. Activators of glucokinase
US20090062242A1 (en) * 2007-08-28 2009-03-05 Agi Therapeutics Plc Methods and compositions for treating gastrointestinal conditions
EP3101018A1 (en) 2007-08-31 2016-12-07 Purdue Pharma L.P. Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2433937A1 (en) 2007-08-31 2012-03-28 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof
US8846929B2 (en) 2007-08-31 2014-09-30 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
US9278967B2 (en) 2007-08-31 2016-03-08 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
US20100216726A1 (en) * 2007-08-31 2010-08-26 Purdue Pharma L.P. Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
EP2433935A1 (en) 2007-08-31 2012-03-28 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2433936A1 (en) 2007-08-31 2012-03-28 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof
US9527840B2 (en) 2007-08-31 2016-12-27 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
US8389514B2 (en) 2007-09-11 2013-03-05 Kyorin Pharmaceutical Co., Ltd. Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
US20110172219A1 (en) * 2007-09-11 2011-07-14 Bei Li Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
US8901112B2 (en) 2007-09-12 2014-12-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
WO2009042177A1 (en) 2007-09-26 2009-04-02 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
US20100222394A1 (en) * 2007-09-28 2010-09-02 Kenichi Asakawa Method for producing pyrazol-3-yl-benzamide derivative
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
US20110009463A1 (en) * 2007-10-17 2011-01-13 Yuri Karl Petersson Geranylgeranyl transferase inhibitors and methods of making and using the same
EP2959917A2 (en) 2007-10-19 2015-12-30 The Regents of The University of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
US20090111863A1 (en) * 2007-10-31 2009-04-30 Esposito Luke A Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
WO2009063821A1 (en) 2007-11-12 2009-05-22 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy quinazoline derivative
WO2009081782A1 (en) 2007-12-25 2009-07-02 Banyu Pharmaceutical Co., Ltd. N-pyrazole-2-pyridinecarboxamide derivative
US9387177B2 (en) 2008-01-09 2016-07-12 Locl Pharma, Inc. Pharmaceutical compositions
US9775837B2 (en) 2008-01-09 2017-10-03 Charleston Laboratories, Inc. Pharmaceutical compositions
US9226901B2 (en) 2008-01-09 2016-01-05 Locl Pharma, Inc. Pharmaceutical compositions
US9498444B2 (en) 2008-01-09 2016-11-22 Locl Pharma, Inc. Pharmaceutical compositions
WO2009089494A2 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
US9789104B2 (en) 2008-01-09 2017-10-17 Locl Pharma, Inc. Pharmaceutical compositions
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
US9789105B2 (en) 2008-01-09 2017-10-17 Locl Pharma, Inc. Pharmaceutical compositions
US9198867B2 (en) 2008-01-09 2015-12-01 Charleston Laboratories, Inc. Pharmaceutical compositions
US9855264B2 (en) 2008-01-09 2018-01-02 Locl Pharma, Inc. Pharmaceutical compositions
US20090232796A1 (en) * 2008-02-20 2009-09-17 Corral Laura G Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US9775889B2 (en) 2008-03-06 2017-10-03 Halozyme, Inc. Methods of treatment of cellulite
US9833498B2 (en) 2008-03-06 2017-12-05 Halozyme, Inc. Methods of treatment of collagen-mediated diseases and conditions
EP2947072A1 (en) 2008-03-17 2015-11-25 Ambit Biosciences Corporation 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea as raf kinase modulator in the treatment of cancer diseases
US9730937B2 (en) 2008-03-17 2017-08-15 Ambit Biosciences Corporation RAF kinase modulator compounds and methods of use thereof
US9320739B2 (en) 2008-03-17 2016-04-26 Ambit Biosciences Corporation RAF kinase modulator compounds and methods of use thereof
US20110118245A1 (en) * 2008-03-17 2011-05-19 Sunny Abraham Raf kinase modulator compounds and methods of use thereof
EP3147281A1 (en) 2008-03-17 2017-03-29 Ambit Biosciences Corporation Quinazoline derivatives as raf kinase modulators and methods of use thereof
US8618289B2 (en) 2008-03-17 2013-12-31 Ambit Biosciences Corporation RAF kinase modulator compounds and methods of use thereof
US8969587B2 (en) 2008-03-17 2015-03-03 Ambit Biosciences Corporation RAF kinase modulator compounds and methods of use thereof
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
US9273055B2 (en) 2008-03-19 2016-03-01 Chembridge Corporation Tyrosine kinase inhibitors
US9249147B2 (